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ABSTRACT
TOWARDS AN ATOMIC LEVEL MODEL OF THE STRUCTURE AND CALMODULIN MEDIATED
ACTIVATION OF EEF-2K

by
Nathan Will
Advisor: Ranajeet Ghose

Eukaryotic elongation factor 2 kinase (eEF-2K), the only calmodulin (CaM) dependent member of
the α-kinase, phosphorylates eukaryotic elongation factor 2 (eEF-2) on a specific residue (Thr-56),
decreasing its affinity for the ribosome and reducing the rate of peptide chain elongation during protein
translation. In contrast to the “release-of-inhibition’ mechanism operative in most CaM-dependent proteins
kinases, the activation of eEF-2K is proposed to occur through a two-step process subsequent to the
engagement of CaM and involves (1) auto-phosphorylation on T348 and (2) engagement of an allosteric
site by phospho-T348 leading to a state with the highest activity towards the substrate eEF-2. The precise
mechanism of this CaM-mediated activation of eEF-2K and the mode of recruitment of the substrate
remain poorly understood.
We utilized a variety of complimentary biophysical techniques including nuclear magnetic
resonance spectroscopy (NMR), small angle X-ray scattering (SAXS), and multiple high-resolution mass
spectrometric (MS) methods to determine the mechanisms through which CaM engages eEF-2K and
induces conformational changes therein en route towards its fully active state. Our integrative approach
provides structural insights into the engagement of eEF-2K by CaM and represents an essential first step
in defining the CaM-dependent activation of eEF-2K in atomistic detail.
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Chapter 1 – Introduction
1.1 – Regulation of Protein Translation
Regulation of protein translation is a key cellular process that is critical for cellular growth,
development, differentiation and survival; its dysregulation is key in a variety of cancers and neurological
conditions such as Alzheimer’s disease.

1–12

While necessary for cellular growth and survival, protein

synthesis is an energetically expensive process that requires strict regulation to maintain cellular
homeostasis.

2,10

The ability to conserve energy by slowing the rate of translation is especially critical

under stress conditions such as starvation or the hypoxic environment of solid tumors.

3,4,6,9,10

Additionally,

regulation of protein synthesis in neurons has been shown to play a critical role in diverse neurological
processes and disorders.11–15 Cells utilize a variety of factors to regulate protein synthesis to respond to
their changing energetic and biosynthetic requirements.

2,10,16–18
2,10,16–18

Protein translation can be divided into three phases: initiation, elongation, and termination.
The most highly regulated of these three phases is initiation.

1,2

During the initiation phase of translation,

7

eukaryotic initiation factors (eIFs) recognize the m G cap structure at the 5’ end and the poly(A) tail at the
3’ end and facilitate pre-initation complex (PIC) binding. The PIC identifies the AUG start codon by
scanning from the 5’ untranslated region (UTR) towards the 3’ end of the mRNA. Once the AUG start
codon is identified, the PIC recruits the 60S subunit of the ribosome to allow initiation of the elongation
phase. Regulation of eIFs, RNA specific binding proteins, and microRNAs as well as structural elements
within the mRNA have been shown to regulate the rate of translation initiation.

1,19–24

This regulation of the

initiation phase allows rapid response to cellular stresses by up-regulating or down-regulating production
of specific proteins.

1,22,23,25

In response to more ribosomes binding to a mRNA molecule due to increased

initiation, the rate of elongation must also increase to avoid the elongation phase becoming the rate
limiting step of translation.

2,23,25,26

Regulation of translation elongation serves multiple purposes. In addition to accommodating
increased rates of translation initiation, decreasing the rate of the elongation during periods of slow
2

initiation allows polysomes to be retained on the mRNA. Having mRNA preloaded with polysomes allows
for rapid increases in the production of proteins when the needs of the cell switch from low to high rates of

1

protein synthesis. Additionally, the rate of elongation is inversely proportional to the error rate during
translation.

27

Thus, slowing down translation increases the fidelity of protein synthesis and further

incentivizes cells to regulate the elongation phase of translation. The elongation phase is also the most
energetically expensive step of protein translation.

2,10

Thus, slowing down global elongation rates is

therefore an effective way to reduce the energy demands of the cells during periods of nutrient
deprivation.
The elongation phase of translation primarily depends on three proteins: eukaryotic elongation
factor-1 alpha (eEF-1α), eukaryotic elongation factor-2 (eEF-2) and eukaryotic elongation factor-3 (eEF3).

2,10,16–18

eEF-1α and eEF-3 are responsible for aminoacyl-tRNA recruitment, while eEF-2 catalyzes the

GTP-dependent translocation of tRNA from the A-site to the P-site of the ribosome.

2,10,16–18

Phosphorylation of eEF-2 at Thr-56 decreases its affinity for the ribosome, thus slowing protein
translation.

17,18,28

An atypical protein kinase called eukaryotic elongation factor 2 kinase (eEF-2K),

previously referred to as calmodulin-dependent protein kinase III, was shown to be responsible for this
phosphorylation.

29–34

eEF-2K is a calmodulin (CaM) dependent protein kinase, which itself is regulated by

diverse mechanisms such as phosphorylation, ubiquitination mediated degradation, pH, and indirectly by
the cytoplasmic calcium concentration through CaM-mediated activation.

35–37

Our long-term is focused on

characterizing the regulation of eEF-2K to further understand its function in normal cellular activity and
disease states such as cancer and depression.
1.2 – Role of eEF-2K in Normal and Diseased States
1.2.1 – Learning, Memory, and Depression
It is well established that protein translation occurs both within the cell body as well as that
dendrites of neurons.

38,39

This allows rapid protein synthesis at synapses, which can be relatively distant

from the cell body of the neuron, and local regulation of protein expression at the synaptic level.

13,39

Synaptic plasticity, through which the strength of a synapse is modified, has been suggested to be
dependent on protein synthesis. Regulation of protein translation has also been shown to play a critical
role in memory consolidation and long term potentiation (LTP), a type of synaptic plasticity in which a
synapse is strengthened in response to patterns of signaling.

2

11–15

Additionally, expression of proteins that

regulate translation have been shown to be increased in specific brain regions associated with the
memory task studied.

21,40

As a result of these functions, regulation of both the initiation and elongation

phases of translation have been implicated in learning and memory formation.

13,21,40–42

The role of protein synthesis in synaptic plasticity as well as the role of calcium ions as a
secondary messenger downstream of neurotransmitter signaling makes eEF-2K well positioned to act as
an intermediary connecting local protein translation to synaptic activity.

43

It has been shown that eEF-2K

directly interacts with Group I metabotropic glutamate receptors (mGluR) through the protein Homer. eEF2K dissociates from mGluR upon activation of the receptor, allowing it to phosphorylate eEF-2 which is
coupled to an increase in the expression of Arc/Arg3.1.

43,44

Mice with kinase dead eEF-2K have been

shown to exhibit attenuation of cortical-dependent associative taste learning, further demonstrating a
direct role of this pathway in learning and memory.

14

In addition to its critical function in normal neuronal signaling, eEF-2K has drawn interest for its
role in the rapid antidepressant effects of ketamine.

43,45,46

Ketamine is an NMDA receptor inhibitor that

exhibits antidepressant activity in patients with depression that is resistant to other treatments.

45

Suppression of spontaneous NMDA receptor mediated neurotransmission induces rapid potentiation of
synaptic responses in the CA1 region of the hippocampus, a region of the brain critical for the activity of
antidepressants.

46

This potentiation requires rapid translation of brain-derived neurotrophic factor (BDNF)

and increased expression of AMPA receptors at the cell surface, which are both dependent on eEF-2K
activity.

46

These results suggest that modulators of eEF-2K activity could be useful in the treatment of

clinical depression.
1.2.2 – Cancer
In addition to its role in normal cellular functions, eEF-2K has been implicated in certain types of
3

cancer such as glioblastomas, medulloblastomas, and breast cancer.

25

It has been shown that eEF-2K

inhibition by siRNA knockdown can sensitize the highly aggressive triple negative MDA-MB-231 tumors to
5

Doxorubicin, a chemotherapy agent, in orthotopic xenograft models. Additionally, it has been suggested
that breast cancer cells can acquire resistance to hypoxia by uncoupling oxygen-responsive signaling
pathways from inhibition of protein synthesis mediated by eEF-2K.

24

It is also thought that eEF-2K has an

integral role in regulation of the Warburg effect by controlling the production of protein phosphatase 2A-

3

A.

47

Addition of eEF-2K inhibitors in combination with chemotherapy agents could be a promising

approach for treating some types of cancer. Contrary to these results, it has also been proposed that
eEF-2K could block tumorigenesis under some conditions.

43

While inhibition of eEF-2K shows promise for

the treatment of a subset of cancer types, more work is needed to fully define the role of eEF-2K in
cancer. Structural characterization of eEF-2K and delineation of the mechanisms through which it
becomes active is critical to understanding the role of this protein in normal biological processes and
disease.
1.3 – Domain Organization of eEF-2K
The structure of full-length eEF-2K is as of yet unknown. A variety of biochemical and
truncation/deletion studies coupled with sequence analyses has defined the organization shown in Figure
1.1. eEF-2K contains an α-kinase domain (residues 116-336) and a SEL-1 like repeat (SLR) containing
C-terminal region connected by an extended, presumably flexible, regulatory loop (R-loop) that contains
multiple up- and down-regulating phosphorylation sites. N terminal to the kinase domain is a region of
which contains a non-canonical CaM binding sequence (Figure 1.1).

35,48–52

Calcium-bound calmodulin

2+

(Ca /CaM) has been shown to interact with residues 79-96 of eEF-2K thus leading it to be referred to as
the calmodulin binding domain (CBD).

36,48,49,53

C-terminal the kinase domain, is the R-loop that contains

the primary site for activating auto-phosphorylation T348. (Figure 1.1).

36,48–50
36,54

been shown to be critical for full activation of the kinase (Figure 1.2).

Phosphorylation of T348 has

The phosphorylated T348 has

been proposed to interact with a conserved phosphate binding pocket on the C lobe of the kinase.

4

37

Figure 1.1 - Domain structure of eEF-2K. The organization of domains within eEF-2K is shown. The
calmodulin binding domain (CBD) is shown in orange, the alpha kinase
domain is shown in yellow, the regulatory R-loop is shown in tan, and the C terminal domain is shown in
blue. Regulatory phosphorylation sites are shown as circles containing the residue number from human
eEF-2K. Sites that increase the activity of eEF-2K are shown in green, while phosphorylation sites that
down regulate the activity are colored red. The kinases that phosphorylate each phosphorylation site are
indicated with arrows. The SEL1 like repeats within the CTD are shown as purple boxes. The domains in
this figure are not drawn to scale.

5

Figure 1.2 – Proposed two-step mechanism for eEF-2K activation. Resting eEF-2K (state S1) forms a
complex with by calcium bound calmodulin (state S2*, an “excited” state that may or may not be
experimentally observable) and undergoes a conformation transition (T1) to a state (S2) that is able to
phosphorylate on T348 in a highly efficient fashion. After rapid auto-phosphorylation on T348 leading to
an excited state S3*, enables phosphorylated T348 to interact with a phosphate binding pocket on the C
lobe of the kinase domain, leading to a second conformation transition (T2), generating a state of eEF-2K
(S3) that has the highest activity towards its substrate eEF-2. Additional regulatory phosphorylation
events modulate this activation process through yet unknown mechanisms.

6

1.3.1 – CaM Binding Domain
The CaM binding domain of eEF-2K (CBD) is located N terminal to the alpha kinase domain, and
has been shown to be critical for activation of eEF-2K (Figure 1.1).

49,51

Most CaM dependent kinases are

activated by CaM sequestering an inhibitory peptide through the so-called “release of inhibition”
mechanism.

55,56

Deletion of the eEF-2K CBD results in a reduction of kinase activity rather than an

increase as would be expected by the removal of an inhibitory segment, suggesting that eEF-2K is
activated by CaM through an alternative mechanism.

49,51,55,57

2+

The structure of the Ca /CaM-CBD

complex, recently published by our lab, determined that the CBD interacts primarily with the C lobe of
53

CaM in an antiparallel 1-5-8 hydrophobic mode reinforced by a pair of electrostatic interactions.
Interestingly, our data suggests that two calcium ions bind to the N lobe of CaM, while the C lobe Ca

2+

binding sites appear to be vacant when in complex with the CBD (see Chapter 5 and Lee, et al.).

53

Additionally, it was shown that W85 of eEF-2K acts as a hydrophobic anchor, stabilizing its interaction
with CaM. Mutation of this residue to serine (eEF-2K W85S) significantly weakens the interaction
between CaM and eEF-2K, as well as reducing eEF-2 phosphorylation in cells.

49,53

1.3.2 – α-Kinase Domain
Historically, eEF-2K was thought to belong to the CaM-dependent protein kinase family (eEF-2K
was

previously

referred

to

as

CaMK-III)

because

autophosphorylation and activation of the kinase (Figure 1.2).

calcium-bound
29,51,58

29,30,50

is

necessary

for

However, it was discovered to contain

an atypical kinase domain which belongs to the α-kinase family.
homology to the canonical protein kinases (CPKs),

CaM

29,30

α-kinases show low sequence

though crystal structures of the catalytic

domains of α-kinases display striking structural similarity to those of canonical protein kinases.

50,59

Similar

to canonical kinases, α-kinase domains contain an N-terminal lobe that is composed primarily of curved
β-sheets and a C-terminal lobe that largely consists of α-helices.
contains the ATP binding site.

50,59

50

A deep cleft between the two lobes

The most significant difference between canonical and alpha kinase

families is a conserved zinc binding motif in the C-terminal lobe of the alpha kinase domain.

7

50,59

1.3.3 – C-terminal Domain
The C-terminal domain (CTD) of eEF-2K is predicted to contain a series of SEL-1 like helical
repeat motifs (SLRs).

48,52

The SLR family is characterized by a series of small and large hydrophobic

residues with no position being completely invariant. Despite the low sequence homology, SLRs display a
characteristic α-helical architecture.

60,61

assembly of macromolecular complexes.

The SLRs with known functions are often involved in the
60,61

Similarly, the CTD of eEF-2K has been suggested to be

important for eEF-2 recruitment to the kinase domain.

48,49,51

It has been demonstrated that the C terminal region of eEF-2K (336-725) can bind eEF-2 in
vitro.

48

Deletion mutations between residues 521-725 have also been shown to inhibit phosphorylation of

eEF-2, but not autophosphorylation or phosphorylation of the MH-1 (a peptide substrate of eEF-2K),
suggesting that this region is involved in eEF-2 binding.

35,48,49,51

Additionally, mutation of two conserved

tyrosines (Y712 and Y713) of eEF-2K to alanine similarly results in loss of its ability to phosphorylate
eEF-2.

48

Our results suggest that these residues are structurally important and that mutation to alanine

results in unfolding of the region (see Chapter 4).

52

Additionally, this region in isolation is not able to

outcompete eEF-2K for eEF-2 binding. Taken together this data suggests that the extreme C-terminus of
the CTD does not contain the complete eEF-2 binding site.

52

1.4 – Regulatory Elements of eEF-2K
The CBD and R-loop of eEF-2K comprise the primary regulatory regions of eEF-2K (Figure 1.2).
2+

eEF-2K activation is a multistep process involving binding Ca /CaM and rapid autophosphorylation of
Thr348 (see Figure 1.2).

36

This primary process is modulated by additional phosphorylation events, e.g.

activation of the mTOR pathway results in inhibitory phosphorylation of eEF-2K within the R-loop on S78,
S359, and S366.
binding.

48,64

48,62,63

Phosphorylation of S78 is thought to inhibit eEF-2K activity by interfering with CaM

S359 is phosphorylated by the CDC2 – Cyclin B

65

as well as stress-activated protein kinase

66

(SAPK) 2a/p38δ . Phosphorylation of eEF-2K by p70 S6 kinase (an mTOR activated kinase) on S366
results in decreased phosphorylation of eEF-2 by eEF-2K in vitro.

63

Also contained within the R-loop are phosphorylation sites that are targeted by AMPK (S398) and
PKA (S500; this is also a site for secondary auto-phosphorylation) that enhance the activity of eEF2K.

64,67

Additionally, the R-loop contains a ubiquitin phospho-degron motif (residues 440-445), which
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target eEF-2K for proteosomal degradation.

37,68–70

Phosphorylation of eEF-2K by AMPK at S398 or PKA

at S500 have been shown to induce ubiquitination and subsequent degradation of eEF-2K. Interestingly,
phosphorylation of eEF-2K on S500, by auto-phosphorylation or by the activity of PKA, results in calcium
independent activation of the eEF-2K-CaM complex.

36

An S500D mutation mimics the behavior of

phosphorylated S500 in cells, providing a convenient tool to study the structural mechanism of calcium
independent activation of eEF-2K.

36

1.4.1 – Calmodulin-mediated Activation of eEF-2K
Typically, CaM-dependent kinases are activated through CaM sequestering an auto-inhibitory
peptide.

55,71

The mechanism of CaM-mediated eEF-2K activation does not appear to follow this model as

no inhibitory peptide has been identified; further the deletion of the CBD does not increase the activity of
eEF-2K, nor does it lead to a substantial increase in the affinity for the substrate eEF-2.

48,49,51

A

combination of steady and pre-steady-state kinetics measurements, in vitro and cell-based assays
suggest that eEF-2K is activated through a two-step process which appears to be unique among the CaM
dependent kinases (this process is schematically illustrated in Figure 1.2).

37

We have demonstrated that

CaM directly interacts with the N lobe of the kinase in addition to the CBD, stabilizing the P-loop, which is
critical for catalysis (Chapter 5). The phosphate-binding pocket of the eEF-2K kinase domain is also
stabilized, likely through an allosteric mechanism (Chapter 5).
1.4.2 – Activation of eEF-2K by Thr348 Autophosphorylation
2+

It has previously been shown that T348 of eEF-2K is rapidly auto-phosphorylated following Ca CaM binding.

36

Mutagenesis studies and structural homology to the MHCK-A kinase domain suggest that

phosphorylated T348 interacts with a phosphate binding pocked on the C-lobe of the eEF-2K kinase
domain.

37

This interaction can be mimicked by inorganic phosphate in the activation of eEF-2K; however

a T348D does not replicate the effect of phosphorylation on T348, suggesting a phosphate-specific
interaction is necessary to activate the kinase.

37

Interestingly, our data suggests that there is allosteric

communication between CaM binding and the phosphate-binding pocket of eEF-2K as described further
in Chapter 5.
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Chapter 2 – Optimization of eEF-2K Expression
2.1 – Serial Truncation of the eEF-2K Kinase Domain Identified a Minimal Construct Necessary for
Kinase Domain Expression
Serial deletion from the N-terminus of eEF-2K (eEF-2K1-358 to eEF-2K111-358) was performed to
identify a minimal N-terminal construct that could be expressed in E. coli. It was found that deletion of the
N-terminal residues of eEF-2K up to 100 could be tolerated, though deletion of 1-110 resulted in no
protein expression. This is in agreement with the homology model

37

of the kinase domain in which E110

of eEF-2K is part of a β-sheet that forms the β-barrel of the kinase domain N-lobe. The model also shows
interaction between the side chains of eEF-2K E110 and R220 (Figure 2.1). While expression was seen
for these N-terminal constructs, they did not appear to be properly folded and a minimal amount was
obtained in the soluble fraction with almost all of the expressed protein being localized in the insoluble
fraction.
2.2 – Co-expression with the eEF-2K C-Terminal Domain Solubilizes the Kinase Domain
It has previously been shown that the C-terminal domain of eEF-2K is critical for eEF-2
phosphorylation.

48,49,51

Additionally, overexpression of the isolated N-terminal constructs encompassing

the kinase domain (KD) in E. coli leads to formation of insoluble aggregates as mentioned above. Despite
extensive buffer screening, no condition that yielded a soluble KD in isolation could be identified. The
buffer conditions screened included pH from 6.5 to 8 (in steps of 0.5 pH) and sodium chloride
concentrations of 100 mM, 250mM, or 500 mM. Further, additives including glycerol (1%, 2%, or 5%),
Triton X-100 (0.1% v/v), magnesium chloride (1 mM), magnesium sulfate (1 mM), calcium chloride (1
mM), were also tested without success. While a small fraction of the KD domain was observed in the
soluble fraction immediately after lysis, it was found to form soluble aggregates on gel-filtration that
rapidly precipitated out of solution upon concentration.
Similarly, efforts to refold the KD from the inclusion bodies also failed to yield soluble protein.
Briefly, the KD (eEF-2K1-358) containing inclusion bodies were harvested from E. coli lysates by
centrifugation at 15,000 × g. The insoluble pellet was resuspended in lysis buffer (20 mM Tris, 100 mM
NaCl, 2 mM DTT pH 7.5). Inclusion bodies were then dissolved with 8 M urea and the insoluble fraction
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was removed by centrifugation at 15,000 × g. The solubilized fraction was then collected and slowly
dialyzed against refolding buffer (20 mM Tris, 100 mM NaCl, 2 mM DTT pH 7.5) overnight. Removal of
urea resulted in the KD precipitating back out of solution. α-kinases have been shown to contain a zinc
ion in the C-lobe.

72

To test if zinc ions were necessary for refolding, 1 mM zinc chloride was added to the

refolding buffer without the desired effect.
Constructs containing the KD (eEF-2K1-358 and eEF-2K71-358) were successfully produced in a
stable folded form by co-expression with the C-terminal domain of eEF-2K (data for eEF-2K1-358 shown in
Figure 2.2). A series of C-terminal domain constructs including eEF-2K470-725, eEF-2K480-725, eEF-2K490-725,
eEF-2K520-725, and eEF-2K562-725 were co-expressed with eEF-2K1-358. The N-terminal construct formed
stable and soluble complexes with eEF-2K470-725, eEF-2K480-725, eEF-2K490-725, and eEF-2K520-725, fully
rescuing the KD from the insoluble fraction. In contrast, addition of eEF-2K490-725 to the lysis buffer was
unable to rescue eEF-2K1-358 from inclusion bodies, suggesting that the presence of the C terminal
domain during expression is important for proper folding of the KD.

Figure 2.1 – Model of the eEF-2K kinase domain suggests E110 is important for kinase domain
folding. A homology model of the eEF-2K KD is shown in green. Deletion of residues eEF-2K 108-110
(cyan) was observed to be deleterious to KD expression. Polar interactions between the side chains of
E110 (cyan) and R220 (red) of eEF2K is shown as a yellow dashed line.
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Figure 2.2 – Co-expression of the eEF-2K kinase domain (eEF-2K1-358) with the C-terminal domain
(eEF-2K490-725) yields a stable heterodimeric complex. (A) Size exclusion traces eEF-2K1-358 coexpressed with eEF-2K490-725 (red) and Full-length eEF-2K (blue) show that the presence of the C-terminal
domain yields a homogeneous well folded protein. (B) SDS PAGE analysis of the major peak of the eEF2K1-358eEF-2K490-725 complex shows that this species contains both the kinase and C terminal domains of
eEF-2K. Elution volumes contained by each fraction are shown in red on the size exclusion trace.
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Co-expression of eEF-2K1-358 (or eEF-2K71-358) with eEF-2K562-725 rescued the former from
inclusion bodies, though this truncated C-terminal domain construct did not lead to the formation of a
stable heterodimeric complex, but rather dissociated during purification, resulting in a soluble eEF-2K562725

and an aggregated eEF-2K71-358 (Figure 2.3). However, addition of eEF-2K490-725 to the N-terminal

construct co-expressed with eEF-2K562-725 resulted in eEF-2K490-725 outcompeting the lower affinity eEF2K562-725 and the formation of a stable eEF-2K1-358•eEF-2K490-725 (Figure 2.4). The advantage of this
system is that it can be utilized to isotopically label only one of the components of the stable complex
since they are expressed independently.

Partial labeling of the complex will reduce the spectral

complexity and facilitate analysis of the complex by NMR. However, further optimization is needed to
improve the efficiency and yield of the resulting complex.
2.3 – Optimization of Solution Conditions for the NMR Analysis of the C-terminal Domain of eEF2K.
While a homology model of the eEF-2K KD has been generated from the structure of another αkinase, MHCK-A, and has been proven to be robust through functional analysis,

37

the C-terminal domain

of eEF-2K does not show significant sequence homology to any entity for which a structure is available in
the PDB. While crystallographic approaches were pursued to determine the structure of the C-terminal
domain; these efforts did not yield protein crystals suitable for structural analysis. Additionally, the largest
C-terminal domain construct that was tested eEF-2K490-725 exhibits concentration dependent aggregation,
exchanging between a monomeric and soluble oligomeric states (Figure 2.5), complicating its NMR.
Hence a divide-and-conquer approach was used to determine the structure of the C-terminal domain by
NMR (see Chapters 3 and 4).
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Figure 2.3 – Co-expression of the N-terminal construct of eEF-2K1-358 with a truncated C-terminal
domain construct (eEF-2K562-725) solubilizes the kinase domain but does not result in a stable
complex. (A) Size exclusion traces of eEF-2K1-358 co-expressed with eEF-2K490-725 rescued the former
from inclusion bodies but eluted as two distinct peaks during size exclusion chromatography using a
Superdex200 10/300 column. The N-terminal construct was found predominantly elute in the void
fractions (~8 mL), while eEF-2K562-725 eluted as a monomeric peak centered at ~16 mL elution volume. (B)
SDS PAGE analysis of the size exclusion chromatography fractions from the void (fractions 1-3) and the
low molecular weight species (fractions 4-7) demonstrate that the KD-containing N-terminal construct was
unable to form a stable complex with eEF-2K562-725.
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Figure 2.4 – A truncated C-terminal domain (eEF-2K562-725) in complex with the KD (eEF-2K1-358) can
be displaced by a longer C-terminal domain construct (eEF-2K490-725) resulting in a stable
heterodimeric eEF-2K1-358eEF-2K490-725 complex. eEF-2K1-358 was co-expressed with eEF-2K562-725
resulting in soluble aggregates. Purified eEF-2K490-725 was added to the soluble fraction and the mixture
was purified over Ni-NTA followed by size exclusion chromatography. (A) Size exclusion traces and (B)
SDS PAGE analyses of the relevant fractions.
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Figure 2.5 – The longest C-terminal construct (eEF-2K490-725) exists as a mixture of oligomeric and
monomeric species. (A) Size exclusion traces of eEF-2K490-725 (CTD) show multiple species that are
isolated during size exclusion chromatography with a Superdex200 10/300 column. The profile suggests
that the C-terminal domain exists as a monomeric as well as soluble aggregate species. Re-injections of
the void or monomeric fractions show similar profiles, suggesting that the CTD exchanges between these
monomeric and soluble aggregate species. (B) SDS PAGE analysis of the size exclusion chromatography
fractions confirm the presence of the CTD in all major peaks observed in the UV trace.
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Several truncated constructs of the C-terminal domain were generated to facilitate their structural
analysis by NMR. Three C-terminal constructs, eEF-2K490-561, eEF-2K562-626, and eEF-2K627-725 were
produced. While eEF-2K490-725 exhibits concentration dependent aggregation, eEF-2K562-621, eEF-2K627-725
and eEF-2K562-725 are monomeric under conditions necessary for NMR analysis. NMR analysis of eEF2K562-621 suggests that it is disordered in solution, though eEF-2K627-725 and eEF-2K562-725 appear to be
folded. We subsequently assigned and solved the structures of eEF-2K627-725 (Chapter 4)

52

and eEF-

2K562-725 (manuscript in preparation; also see Chapter 5).
Extensive efforts to find conditions in which eEF-2K490-725 exists as a homogenous monomeric
species at concentrations suitable for NMR studies have so far been unsuccessful. Dynamic light
scattering and size exclusion chromatography were used to screen buffer conditions in an attempt to
identify buffer conditions under which this domain is monomeric at concentrations optimal for NMR
analysis. Variable including pH (6.5 or 7.5), sodium chloride concentration (0 mM, 100 mM, 200 mM, 500
mM), as well as addition of glycerol (1% and 5%) were screened. No conditions were found that
completely prevented oligomerization of the C-terminal domain. Coupled with the fact that the C-terminal
domain form a stable heterodimeric complex with the N-terminal constructs that include the KD, suggests
that the interface responsible for this aggregation is buried or otherwise inaccessible in the context of the
full-length protein.
2.4 Cloning, Expression and Purification of Truncated Constructs of eEF-2K.
SUMO-tagged N-terminal constructs of eEF-2K (eEF-2K1-358 or eEF-2K71-358) were cloned into a
pET28a expression vector (Novagen) between the NdeI and HindIII restriction sites to generate His6SUMO tagged constructs and transformed into BL21 DE3 E. coli cells (New England Biolabs) for
expression. The cells were plated on ampicillin plates and incubated overnight at 37 °C. SUMO-tagged Cterminal domain constructs (eEF-2K490-725 and eEF-2K562-725) were similarly cloned into pET15b vector
(Novagen) between the NdeI and BamHI restriction sites and transformed into BL21 DE3 E. coli cells
(New England Biolabs) for expression. A single colony was inoculated into 10 mL of LB medium
(containing 100 mg/L of ampicillin for C-terminal domain expression, 30mg/L kanamycin for Kinase
domain expression, or 100 mg/L of ampicillin and 30mg/L kanamycin for co-expression of the two
constructs) and grown overnight at 37 °C. The overnight culture was inoculated into 0.4 L of LB medium
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and grown at 37 °C until the culture reached an A600 of 0.8, at which point the temperature was reduced to
18 °C and expression was induced by the addition of IPTG to a final concentration of 0.4 mM. Post
induction, the cells were grown for 16 hours and harvested by centrifugation at 2820 × g for 30 minutes.
Unless otherwise stated, the cell pellet was re-suspended in 50 mL of cold lysis buffer (20 mM Tris,
200mM NaCl, 0.1% β-mercaptoethanol, 0.1% Triton X-100, 10 mM imidazole and 1 tablet of Roche
Complete Mini EDTA-free Inhibitor, at pH 7.5); all subsequent steps described below were carried out at 4
°C. The cells were lysed by sonication and cell debris was removed by centrifugation at 10800 × g for 30
minutes. The soluble lysate was added to a 5 mL (bed volume) Ni-NTA affinity column (Qiagen)
previously equilibrated with lysis buffer and incubated for 1 hour with end-over-end rotation. The column
was then washed extensively with washing buffer (20 mM Tris, 200 mM NaCl, 0.1% β-mercaptoethanol,
20 mM imidazole, pH 7.5) and the bound protein was subsequently eluted with 50 mL of elution buffer (20
mM Tris, 200mM NaCl, 0.1% β-mercaptoethanol, 250 mM imidazole, pH 7.5). The His6-SUMO tag was
cleaved by the addition of ULP1 protease (1ug per 50 mL of elution) during overnight dialysis into
cleavage buffer (20 mM Tris, 200 mM NaCl, 0.1% β–mercaptoethanol, pH 7.5). The effectiveness of
cleavage was monitored by 12% SDS-PAGE gels. The purified protein was then concentrated using spin
columns and further purified by gel filtration chromatography using a Superdex 200 10/300 GL (GE
HealthCare Biosciences) column pre-equilibrated with a buffer containing 20 mM Tris, 200 mM NaCl, 2
mM DTT.
2.5 – Conclusions
It was found that the KD of eEF-2K could not be isolated in stable, soluble form when expressed
in isolation in E. coli. However, co-expression of several KD-containing N-terminal constructs with multiple
C-terminal domain constructs lead to solubilization, either as aggregates when using the shortest Cterminal construct, eEF-2K562-725, or a stable heterodimeric complex when using the longer, eEF-2K490-725.
In fact the KD co-expressed with eEF-2K562-725 could be retrieved in vitro from the soluble aggregates
containing mixtures of eEF-2K1-358 and eEF-2K562-725 through incubation with eEF-2K490-725 forming a
stable eEF-2K1-358•eEF-2K562-725 complex. The fact that each component of the latter complex were
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separately expressed allows for differential isotope labeling of each component, thus simplifying NMR
analyses.

Chapter 3 – Overview of Biophysical Methods
3.1 – Mass Spectrometry Methods
3.1.1 – Native Mass Spectrometry
Native Mass spectrometry (Native MS) is an electrospray ionization based technique (ESI-MS) in
which the protein or macromolecular assembly is interrogated under non-denaturing conditions.

73–75

This

method preserves the tertiary and quaternary structure of macromolecular assemblies, allowing the direct
analysis of the stoichiometry of protein complexes.

73–76

Once the sample is injected into the spectrometer,

the droplets containing the protein or macromolecular complex shrinks as water and volatile buffer
components dissociate. After desolvation, only the protein(s) and nonvolatile buffer components remain,
the mass of which is subsequently determined.

73–76

One limitation of this method is the requirement that a

volatile buffer, typically ammonium acetate or ammonium bicarbonate, be used to reduce adduct
formation during the desolvation process.

77

However, low concentrations of non-volatile buffer

components can typically be tolerated, especially if nanospray capillaries are used during electrospray
ionization.

73,77

The charge state distribution from native MS has been shown to correlate to the solvent
accessible surface area of a protein.

78

An empirical formula has been developed to calculate the solvent

accessible area of a protein using charge state analysis.

78

Unfolded proteins or protein states that have a

larger solvent accessible surface area are observed to display higher charge states compared to a more
compact species.
protein sample.

73,77,78

Therefore native MS can be used to assess the folding and aggregation state of a

73–76,79

3.1.2 – Hydrogen/Deuterium Exchange Mass Spectrometry
Hydrogen/deuterium mass spectrometry (HXMS) is a powerful tool that measures the exchange
of labile protons for a protein or peptide.

80–89

HXMS experiments are performed by incubating a protein in
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a buffered D2O solution for defined lengths of time. During this incubation period, the exchangeable
protons in the protein are gradually replaced with deuterium, resulting in a 1 Da increase in the mass of
the protein per deuterium incorporated.

80–89

Analysis of the resulting isotopic envelope can be used to

determine the average mass of the species compared to the control sample and calculate the average
number of hydrogen atoms exchanged for deuterium during the incubation.

80–89

The exchange rate of a labile proton within a folded protein is determined by multiple factors,
including the intrinsic exchange rates of the residue, solvent exposure, and hydrogen bonding.

80–89

The

proton exchange rate is also pH sensitive. Backbone amides have a minimum exchange rate at a pH of
~2.5.

81,82,86,87,90

Therefore, acidifying the sample to a pH of ~2.5 and reducing the temperature can

quench the exchange reaction of backbone amide protons.

81,82,86,87,90

This allows the sample to be

desalted and fractionated with chromatography methods such as reverse phase chromatography while
preserving the deuteration state of backbone amides. Unfortunately, The N-terminus and labile side chain
protons rapidly exchanged at this pH, resulting in loss of information about the exchange rates of these
protons.

81,88,91

Uptake of deuterium by a protein can be determined for either the intact protein (intact mass
HXMS) or fragmented proteins (local HXMS).

80,81,92,82–89

Intact mass HXMS yields information about the

deuterium uptake averaged over every residue within the protein. Thus global HXMS analysis provides
information on whether different states of a protein are globally more or less dynamic i.e. have different
average exchange rates.

80,81,92,82–89

Intact mass HXMS is also useful for determining the incubation time

ranges during which the proteins show moderate or rapid exchange and after which the protein becomes
saturated with deuterium as well as optimizing experimental conditions for a particular system.

82,87,91

Because the global rate of exchange is the average of all exchangeable hydrogens within the protein,
care must be taken when interpreting the data. For example, if ligand binding to a protein induces one
region to become more dynamic and another to become equally more protected, the resulting increase
and decreased in local exchange rates would be canceled out in the global analysis.

82,89,90

Local HXMS

can be used to identify these local changes in protection.
Local HXMS differs from intact mass HXMS in that the protein is fragmented, allowing for analysis
of the exchange rates for individual peptides within a protein.
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80–87,89

Fragmentation is generally achieved

either a proteolytic digestion (referred to as the bottom-up approach) or through gas-phase fragmentation
after ionization within the spectrometer (top-down approach).

93–95

The bottom-up approach fragments the

protein after exchange and before injection into the mass spectrometer, which allows the resulting
peptides to be isolated before mass determination (Figure 3.1).

93–95

Identification of retention times for

peptides from a reference sample facilitates the identification of the peptides from exchange
experiments.

90,91

Though the observed peptides are often several residues long, analysis of overlapping

peptides allow exchange rates of smaller regions or even single residues to be determined (Chapter 5).

90

There are some limitations to HXMS experiments. Sufficient peptide coverage is critical for the
analysis of HXMS data. Therefore finding conditions that yield enough assignable peptides is required for
analysis of the regions of interest within a protein.

91,94

Factors such as residence time on the protease

column and denaturants in the quench solution can be varied to optimize the proteolysis.

90,91

The low

temperature and pH required to quench the exchange reaction limits the commercially available
proteases that can be utilized for these experiments. Pepsin, alone or in combination with fungal protease
XIII, fungal protease XVIII or Plasmepsin 2, is commonly utilized due to their relatively non-specific
proteolytic activity at low pH.

96

“Back exchange” of the deuterium back to hydrogen during the proteolysis

and chromatography steps is another factor that can complicate analysis of HXMS data.

89–91

Though,

comparison of two or more states and optimization of the chromatography protocol can generally
circumvent these limitations.
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Figure 3.1 - Schematic representation of a typical hydrogen deuterium exchange experiment. Both
global and local HXMS exchange experiments are illustrated. First, the protein sample (S1) is diluted with
D2O and incubated for a defined exchange time (S2). To stop the exchange, the sample is cooled on ice
to ~4°C and quenched with a formic acid solution that reduces the pH of the sample to 2.4 (S3). The
sample is then subjected to reverse phase chromatography before being injected directly into an ESI
mass spectrometer. For local exchange, the protein is digested with an immobilized pepsin column before
the chromatography steps. To reduce back exchange, the sample is always kept at ~4°C after quenching.
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It is advantageous to compare relative exchange rates between different states of a biomolecule
89–91,94

rather than absolute deutrium uptake.

Relative uptake does not rely on exact determination of the

back exchange, assuming the back exchange is the same for both states. Accurate correcting for back
exchange requires a fully deuterated form of the protein, which can be technically challenging to prepare.
Relative uptake measurements do not suffer from this difficulty because the back exchange generally is
expected to be the same for both samples. Thus, the difference in deuterium uptake between two states
is expected to be preserved despite low to moderate back exchange. Therefore comparing multiple states
eliminates the requirement for precisely determining back exchange rates.
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82,91,94

3.1.3 – Chemical Crosslinking Mass Spectrometry
Chemical crosslinking mass spectrometry can be used to identify interaction sites between two
proteins. Chemical cross-linkers generate a covalent bond between specific protein residues.

75,97–104

Crosslinking reagents can be categorized by a variety of factors including functional groups that define
what they react with, linker length, cleavability, and additional modifications such as affinity tags.

103,105

For

example, bis(sulfosuccinimidyl)suberate (BS3) contains two amine-reactive N-hydroxysulfosuccinimide
(sulfo-NHS) esters (Figure 3.2A) separated by an 8-carbon spacer (yielding a maximum spacer arm
length of 11.4 Å).

104

The linker length defines the maximum length between the hydrodynamic radii of the

two reactive groups.

104,106

A special class of these chemical modifiers are referred to as “zero-length” crosslinkers (Figure
3.2B)

103,105

include carbodiimides e.g. 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

105

EDC

catalyzes the peptide bond formation between carboxyl groups (aspartate or glutamate side chains and
the C-terminus) to amine groups (lysine side chains or the N-terminus; Figure 3.2B). EDC first reacts with
a carboxyl group to form a reactive, though relatively unstable, O-acylisourea intermediate (Step 1 in
Figure 3.2B). N-hydroxysulfosuccinimide (sulfo-NHS) reacts with the O-acylisourea intermediate to yield a
more stable sulfo-NHS ester intermediate (Step 2 in Figure 3.2B). The sulfo-NHS ester can then be
attacked by an adjacent amine group, which results in amide bond formation between the carboxyl and
amine group (Step 3 in Figure 3.2B). The reaction requires close proximity of the two side chains, thus
reducing the maximum possible distance between two cross-linked residues.

102

Crosslinked proteins can be digested with specific proteases (such as trypsin, chymotrypsin, etc.)
to generate peptides, which can then be analyzed by LC-MS.

100,102,104

Software packages have been

developed to search for crosslinked peptides within the resulting mass spectra.

107,108

The suspected

crosslinked peptides can then be validated by analysis of the fragmentation data as well as comparison to
a reference sample.

101

Chemical crosslinking allows identification of the interface between subunits within

a complex and yields a sample of the interactions that occur in solution.
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Figure 3.2 - Mechanism of Crosslinking Reactions. (A) The reaction between sulfo-NHS ester (such
BS3) and the amine of a protein target is shown. In the case of BS3, the R group represents a fourcarbon linker attached to an identical sulfo-NHS ester at the other end. (B) The mechanism of the
EDC/sulfo-NHS “zero length” crosslinking reaction is shown. Step 1 shows the reaction of EDC with a
carboxyl group to form an O-acylisourea intermediate. In step 2, N-hydroxysulfosuccinimide (sulfo-NHS)
reacts with the O-acylisourea intermediate to form a sulfo-NHS ester intermediate. The sulfo-NHS ester
reacts with a primary amide group to form amine bond between the primary amine and the carboxyl
groups. (Figure 3.2 was modified from Sinz, A. 2006)

98
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5.2 – NMR Methodology
Nuclear magnetic resonance (NMR) spectroscopy is commonly used to characterize the solution
state structure and dynamic behavior of proteins. NMR is especially useful for structural characterization
of macromolecular systems that are dynamic or otherwise difficult to crystalize. Additionally, NMR
methods have been developed to interrogate the dynamic behavior of proteins and other biological
molecules at time scales ranging from picosecond to seconds and beyond.

109

Isotope enrichment

methods as well as residue specific labeling schemes and ever improving pulse sequences have allowed
analysis of increasingly complex systems. The purpose of this section is to provide a brief overview of the
approaches used above. Many texts are available which provide in depth explanations of the methods
and the underlying physics behind these phenomena.

110–117

5.2.1 – NMR Assignments
Utilizing complementary multidimensional heteronuclear NMR experiments is the most common
approach for assigning protein chemical shifts, especially for large proteins.

116,118

These experiments

typically utilize one- or two-bond couplings to correlate the backbone amide H and N chemical shifts to
110,116,118

the chemical shifts of the backbone and/or sidechain carbons.

This approach has significantly

improved upon previous methods especially for assigning larger proteins. Pulse sequences have been
developed to determine the resonances of specific combinations of atoms within a residue or pair of
sequential residues. For example, the CBCA(CO)NH experiment will report the Cα and Cβ chemical
shifts of the (i-1) residue associated with backbone amide of the (i) residue.

119

The HNCACB, on the other

hand, reports the Cα and Cβ chemical shifts of both the (i) and (i-1) residue.

120

By comparing the Cα

and Cβ chemical shifts determined by these two experiments, it is possible to determine the sequential
1

order of backbone amide H and
chemical shifts to

13

15

N chemical shift pairs. Additionally, comparison of the observed

C chemical shift statistics of the Cα and Cβ carbons facilitates identification of the

amino acid type. Comparison of the peptide sequences generated from this analysis to the sequence of
the protein can then be used to unambiguously assign the observed chemical shifts to specific residues
within the protein. Similarly, H(CCO)NH-TOCSY, (H)C(CO)NH-TOCSY, and HCCH-TOCSY can be used
to assign chemical shifts for the remaining side chain positions as well as to resolve ambiguous backbone
assignments.

110,116,118
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5.2.2 – Protein Structure Determination by NMR
While the generation of complete or near-complete chemical shift assignments of backbone and
side chain positions represents the first step in the NMR analysis of proteins and protein complexes,
additional constraints are necessary for the generation of structural models from NMR data. Nuclear
Overhauser effect (NOE) derived distance constraints are typically used in conjunction with chemical shift
derived backbone dihedral angle constraints to generate structure models.
constraints are obtained from

13

C and/or

15

111,121

Generally, these

N-edited 3- and sometimes, 4-dimensional NOESY

experiments to simplify spectral complexity and ease the semi-quantitative analysis of crosspeak
intensities. In some cases, NOE-derived distance constraints are supplemented by orientational
constraints derived from residual dipolar couplings (RDCs). These latter constraints often compensate for
the lack sufficient long-range (> 4 residues) NOE-based distance constraints that are crucial in the
determining the overall fold of the protein in question.

118,122

As will be described in Chapters 4 and 5, we relied on both NMR-based as well as MS-based
approaches to characterize the structure and interactions of eEF-2K.
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Chapter 4 – Structure of the C‑Terminal Helical Repeat Domain of Eukaryotic Elongation Factor 2
Kinase

The contents of this chapter were published as:
Will et al. Structure of the C-terminal helical repeat domain of eukaryotic elongation factor 2
kinase. Biochemistry 55, 5377–5386 (2016)
©

2016 American Chemical Society (reproduced with permission)

3.1 – Abstract
Eukaryotic elongation factor 2 kinase (eEF-2K) phosphorylates its only known physiological
substrate, elongation factor 2 (eEF-2), which reduces the affinity of eEF-2 for the ribosome and results in
an overall reduction in protein translation rates. The C-terminal region of eEF-2K, which is predicted to
contain several SEL-1-like helical repeats (SLRs), is required for the phosphorylation of eEF-2. Using
solution nuclear magnetic resonance methodology, we have determined the structure of a 99-residue
fragment from the extreme C-terminus of eEF-2K (eEF-2K627−725) that encompasses a region previously
suggested to be essential for eEF-2 phosphorylation. eEF-2K627−725 contains four helices, of which the first
(αI) is flexible, and does not pack stably against the ordered helical core formed by the last three helices
(αII−αIV). The helical core is structurally similar to members of the tetratricopeptide repeat (TPR) family
that includes SLRs. The two penultimate helices, αII and αIII, comprise the TPR, and the last helix, α
IV, appears to have a capping function. The eEF-2K627−725 structure illustrates that the C-terminal deletion
that was shown to abolish eEF-2 phosphorylation does so by destabilizing αIV and, therefore, the helical
core. Indeed, mutation of two conserved C-terminal tyrosines (Y712A/Y713A) in eEF-2K previously
shown to abolish eEF-2 phosphorylation leads to the unfolding of eEF-2K627−725. Preliminary functional
analyses indicate that neither a peptide encoding a region deemed crucial for eEF-2 binding nor isolated

28

eEF-2K627−725 inhibits eEF-2 phosphorylation by full-length eEF-2K. Taken together, our data suggest that
the extreme C-terminal region of eEF-2K, in isolation, does not provide a primary docking site for eEF-2.
3.2 – Introduction
Eukaryotic elongation factor 2 kinase (eEF-2K)

29–31

(725 residues, 99 kDa) is a calmodulin-dependent

member of the α-kinase family that regulates protein synthesis through phosphorylation of its only known
cellular target, eukaryotic elongation factor 2 (eEF-2), on a specific threonine residue (T56).

29–34,58

This

post-translational modification impedes the interaction between eEF-2 and the ribosome, thereby
18,32,33

reducing global protein synthesis rates.

The regulation of protein translation by eEF-2K is thought to

be important in a host of physiological processes, including the regulation of cell cycle progression,
synaptic plasticity, learning, and the formation of memory.

13,14,41

65

It has been suggested that eEF-2K,

under conditions of nutrient deprivation, mediates an adaptive response in tumors, thus promoting tumor
5

growth. The role of eEF-2K in the pathogenesis of cancer is further supported by several studies
correlating eEF-2K expression with low survival rates in a variety of cancers such as glioblastomas,
3

medulloblastomas, and breast cancer.

25

Recent results suggest that eEF-2K plays a critical role in

regulating the Warburg effect by modulating the synthesis of protein phosphatase 2A-A (PP2A-A).

47

In

addition, eEF-2K function has been implicated in a variety of neurological conditions such as Alzheimer’s
disease

123,124

and clinical depression

125

. Using a combination of deletions and site-directed mutagenesis

supported by bioinformatic tools, previous studies have suggested a domain structure of eEF-2K

49,51

(Figure 4.1). eEF- 2K contains a sequence N-terminal to its catalytic kinase domain (KD) that takes part in
2+

a high-affinity interaction with Ca -loaded calmodulin (CaM).

53

This interaction initiates a conformational

change allowing the efficient autophosphorylation of a specific threonine (T348, dark green in Figure 4.1)
located on a regulatory loop (R-loop) C-terminal to the KD. A subsequent interaction involving the
phosphorylated T348 and the KD leads to a further conformational change, resulting in the fully active
state of the kinase.

37

The eEF-2K KD bears significant sequence homology with the catalytic domains of

other α-kinases, e.g., the ion-channel kinase TRPM7 (28% identity)

126

and myosin heavy chain kinase A

59

(MHCK-A, 34% identity) from Dictyostelium discoideum . In addition to T348, the R-loop, which is
predicted to be disordered, contains other phosphorylation sites that lead to negative (red in Figure 4.1)

29

or positive (green in Figure 4.1) regulation

12

of kinase activity. The C-terminal region/domain (CTD) of

eEF-2Ks predicted to contain several SEL-1-like helical repeats (SLRs), a structural motif that is known to
provide a platform for protein−protein interactions.

60

This region, which is essential for the physiological

function of eEF-2K both in modulating kinase activity and in recognizing substrate,

48

shows poor

homology with sequences for which structural information is available. The CTD has been shown to
regulate the activity of eEF-2K, and it has been suggested that this occurs through a direct interaction
with the KD.

48

It has been further shown that an eEF-2K construct (336−725, which excludes the N-

terminal CBD and the KD but includes the R-loop and the entire CTD) can be coprecipitated with eEF-2,
suggesting that this region contains the binding site for eEF-2.

51

Deletion of the extreme C-terminus

(residues 711−725) of eEF-2K results in the loss of kinase activity against eEF-2 but not against a peptide
substrate, MH-1, leading to the suggestion that this region plays a role in recognizing eEF-2.

48

Given the

fact that the structure of intact full-length eEF-2K is not yet available, we undertook the characterization of
the structural elements comprising the CTD using solution nuclear magnetic resonance (NMR)
spectroscopy. The rationale behind this choice is twofold. (1) While a model for the KD has been derived
using the structures of TRPM7 and MHCKA as templates and this model has proven to be robust for the
analysis of small molecule functional modulators,

127,128

the poor similarity of the CTD sequence with those

of known structure makes homology modeling difficult. (2) A structure of the CTD or of relevant fragments
thereof should provide a basis for deciphering the nature of the interaction between the CTD and the KD
and indeed with the substrate, eEF-2.

30

Figure 4.1. Schematic representation of the domain structure of eEF-2K. The N-terminal calmodulinbinding domain (CBD), catalytic kinase domain (KD) and the C-terminal domain (CTD) are shown. The
region between the KD and CTD is known as the regulatory loop (R-loop) that contains both upregulating
(green) and downregulating (red) phosphorylation sites. The kinases that target these phosphorylation
sites are indicated. The N-terminal S78 can act as both an activating as well as an inhibitory site. T348,
the autophosphorylation of which constitutes a key step in the activation eEF-2K is shown in dark green.
The specific C-terminal mutations, discussed in the text that either reduce (red) or enhance (green) eEF-2
phosphorylation, are indicated. The lower panel shows the location of the PFAM-predicted SEL-1 like
repeats (SLRs). The eEF-2K627-725 construct (shaded light blue, 627-725) includes the last two predicted
SLRs.

31

As a first step toward this goal, we obtained the solution structure of a 99-residue C-terminal
fragment of eEF-2K (residues 627−725, denoted eEF-2K627−725) that encodes the final two SLRs predicted
by an analysis of the eEF-2K sequence against the PFAM database

129

(Figure 4.1). This construct

includes the region (residues 711−718) that has been suggested to be required for the phosphorylation of
eEF-2.

48

The structure of eEF-2K627−725, presented here, along with our recent structure of the eEF-2K

CBD in complex with Ca2+/ CaM,

53

represents the first high-resolution structural information for the

unique enzyme that is eEF-2K. Our data provide a structural framework for interpreting the effects of the
deletions and/or mutations at the C-terminus of eEF-2K that impede its ability to phosphorylate eEF-2.

48

These data, in combination with preliminary competition assays presented here, suggest that this loss of
activity toward eEF-2 is the result of structural destabilization of eEF-2K resulting from the delections
and/or mutations rather than a loss of the primary binding site for eEF- 2 that does not appear to be
contained uniquely within the isolated eEF-2K627−725 fragment.
3.3 - Materials and Methods
3.3.1 - Protein Expression and Purification
The C-terminal fragment of eEF-2K (S627−E725, 99 residues, eEF-2K627−725) was cloned into a
pET15b expression vector (Novagen) between the NdeI and BamHI restriction sites and transformed into
BL21 DE3 cells (New England Biolabs) for expression. The cells were plated on ampicillin plates and
incubated overnight at 37 °C. A single colony was inoculated into 10 mL of M9 minimal medium and
grown overnight at 37 °C. After centrifugation at 4 °C and 4000g for 20 min, the cells from the starter
culture were inoculated into 0.5 L of M9 minimal medium containing 1 g of
chloride and 2g of

13

15

N-labeled ammonium

C-labeled glucose as the sole nitrogen and carbon sources, respectively. The cells

were grown at 37 °C until the culture reached an OD600 of 0.8, at which point the temperature was
reduced to 18 ° C and expression was induced by addition of 0.4 mM isopropyl β -D-1thiogalactopyranoside (IPTG). Cells were subsequently grown for 20 h and harvested by centrifugation at
4 °C and 3000g for 30 min. Harvested cell pellets were resuspended in 40 mL of lysis buffer [20 mM
Tris, 0.1% β-mercaptoethanol, 10 mM imidazole, and 1 tablet of Roche Complete Mini EDTA-free
inhibitor (pH 7.5)]; all subsequent steps described below were performed at 4 °C. The cells were lysed

32

by sonication, and cell debris was removed by centrifugation at 4 °C and 15550g for 30 min. The soluble
lysate was added to a 3 mL (bed volume) Ni-NTA affinity column (Qiagen) previously equilibrated with
lysis buffer and incubated for 1 h on a rotary agitator. The column was then washed extensively with
washing buffer [20 mM Tris, 0.1% β - mercaptoethanol, and 20 mM imidazole (pH 7.5)], and
subsequently, the bound protein was eluted with 50 mL of elution buffer [20 mM Tris, 0.1% β mercaptoethanol, and 250 mM imidazole (pH 7.5)]. The N-terminal His6 tag was cleaved with the addition
of ∼50 units of human α-thrombin (Enzyme Research Laboratories) while being dialyzed overnight into
cleavage buffer [20 mM Tris, 0.1% β-mercaptoethanol, and 5 mM EDTA (pH 7.5)]. The effectiveness of
cleavage was monitored by 15% sodium dodecyl sulfate−polyacrylamide gel electrophoresis
(SDS−PAGE) gels. The cleavage reaction was quenched by the addition of 0.1 mM AEBSF (SigmaAldrich). The protein was then concentrated using spin columns and further purified by gel-filtration
chromatography using a Superdex 75 10/300 GL (GE HealthCare Biosciences) column pre-equilibrated
with NMR buffer [50 mM phosphate and 4 mM DTT (pH 6.5)]. Fractions containing pure eEF-2K627−725
were collected and concentrated using a spin column to final concentrations ranging from 300 to 600 μM
for NMR experiments.
The Y712A/Y713A, Y712A, Y713A, and E717A mutants of eEF-2K627−725 were generated using
the QuikChange Multi Site-Directed Mutagenesis Kit (Agilent) and appropriately designed primers. The
mutated plasmid was transformed into XL10-Gold ultracompetent Escherichia coli cells supplied with the
kit. For protein expression, Y712A/Y713A and E717A constructs were transformed into BL21 DE3 cells
and expressed using the protocol described above for wild-type eEF-2K627−725. The Y713A mutant was
expressed at 37 °C for 4 h after IPTG induction. The Y712A construct did not express under any of the
conditions tried. The purification protocol for all of the mutants was the same as that used for the wildtype protein, as described above.
3.3.2 - Resonance Assignment
All NMR experiments were conducted at 25 °C using Varian Inova (600 MHz) or Bruker Avance
spectrometers (600, 700, and 800 MHz) equipped with cryogenic probes capable of applying pulsed-field
gradients along the z-axis. All NMR data were processed and analyzed using the NMRPipe

33

130

and

NMRViewJ
standard

131

software suites, respectively. Backbone resonance assignments were obtained using

backbone-directed

triple-resonance

strategies

116

using

HNCO/HN(CA)CO

and

HNCACB/CBCA(CO)NH pairs. Side chain resonance assignments were obtained though H(CCO)NHTOCSY, (H)C(CO)NH-TOCSY, and HCCH- TOCSY.

116

Details of these experiments are provided in

Table 4.1. Distance constraints were obtained from three-dimensional (3D)
13

C-aliphatic edited, and

13

1

N-edited NOESY-HSQC,

C-aromatic NOESY-HSQC experiments, using mixing times of 150 ms in all

cases. Aromatic assignments were obtained via
two- dimensional (2D)

15

13

C-aromatic edited NOESY-HSQC supplemented with a

1

H− H NOESY experiment.

13

C-aliphatic edited and homonuclear NOESY

experiments were performed in D2O-based buffers. Experimental details of the NOESY experiments are
provided in Table 4.2. Methionine ε-methyl groups were assigned using the NOESY experiments in
combination with 3D HMBC and 3D LRCH experiments

132

(see Table 4.1 for details). The assigned

chemical shifts have been deposited in the BMRB as entry 30135. Measurement of Residual Dipolar
Couplings. Partially oriented samples for residual dipolar coupling (RDC) measurements were obtained
by adding Pf1 phage (ASLA Ltd.)

119

directly to the NMR sample (the pH was manually adjusted to 6.5) for

a final concentration of 15 mg/mL phage and 300 μM eEF-2K627−725. Amide
at 600 MHz using 2D

15

N IPAP

122

15

1

N− H RDCs were collected

pulse sequences (spectral windows of 12 and 28 ppm with 512 and 128

complex points in the direct and indirect dimensions, respectively) on both aligned (2H quadrupolar
splitting of ≈23 Hz) and isotropic samples. The measured RDCs were analyzed using the PALES software
suite

133

and utilizing the initial structural ensemble generated using distance and dihedral angle

constraints only.
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Table 4.1. Parameters for Backbone and Sidechain Assignment Experiments
Point
Experiment

Nucleu

Point

SW
s

Nucleu

Point

SW
s

s

Nucleu

Fiel

s

d

SW
s

s

HNCO

512

13

1

H

28

10

13

C

28

26

15

N

600

HN(CA)CO

512

13

1

H

28

10

13

C

28

26

15

N

600

CBCA(CO)NH

512

13

1

H

48

10

13

C

28

26

15

N

600

HNCACB

512

13

1

H

48

10

13

C

28

26

15

N

600

512

13.3

1

H

80

26

15

N

28

11

1

H

600

512

13.3

1

H

80

26

13

C

29

H(CC)(CO)NH
-TOCSY
(H)CC(CO)NH

43.

-TOCSY

N

600

13

C

800

13

C

700

H

700

7
13.3

HCCH-TOCSY

15

512

1

H

32

32

13

C

40

1

H

8

4.0

13

C

128

13

5
3D-HMBC

512

10.0

18.
0

3D-LRCH

512

10.0

1

H

8

4.0

13

7.4
C

128

1

0

Fields are in MHz, points are complex points and sweep-widths (SW) are in ppm. All experiments were
performed at 25 °C in H2O, with the exception of the HCCH-TOCSY, that was collected in a D2O-based
buffer.
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Table 4.2. Parameters for 2D and 3D NOESY Experiments
Experime
nt

Point
s

SW

15

1024

11.
6

1

1024

10

1024
4096

1

N, H
NOESYHSQC
13
Caromatic
NOESYHSQC
13
Caliphatic
NOESYHSQC
1
1
H, H
NOESY
The

15

Nucleu
s

Point
s

SW

H

64

26

15

1

H

54

28

11

1

H

64

13.
9

1

H

512

N-edited NOESY and the

buffers, the

13

13

Nucleu
s

Point
s

SW

Nucleu
s

Fiel
d

H

Mixin
g
Time
120

N

224

11.
6

1

13

C

128

10

1

H

150

700

61

13

C

128

11

1

H

150

600

13.
9

1

H

-

-

-

150

800

800

Caromatic-edited NOESY experiments were recorded in H2O-based

Caliphatic-edited and the 2D NOESY experiments were performed in D2O-based buffers.

Mixing times are in ms.
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3.3.3 - Relaxation Measurements.
15

N longitudinal (R1) and transverse (R2) relaxation rates were obtained at 600 MHz using

standard pulse sequences.

110

The following relaxation delays were used: 10, 50, 100, 200 (twice), 400,

500, 700, and 900 ms (twice) for R1 and 0.0, 17 (twice), 34, 51, 68, 85, 102 (twice), 136, 170, and 203 ms
1

15

for R2. Steady-state { H}− N nuclear Overhauser effect (NOE) experiments were also performed at 600
MHz using the pulse sequence of Ferrage et al.

134

using a saturation time of 5 s and an overall delay of 7

s. All relaxation experiments used sweep widths of 12 and 28 ppm with 512 and 128 complex points in
the direct and indirect dimensions, respectively.
3.3.4 - Structure Calculations
Structure calculations were performed using ARIA2.3 (CNS1.2) following published protocols.
Briefly, TALOS+

136

13

15

Cβ,

13

C, and

1

1

was used to obtain dihedral angle constraints from chemical shifts ( H, Hα,

13

135

Cα,

N), and peak intensities of the 3D NOESY experiments were introduced directly into

ARIA to derive ambiguous distance restraints. Spin-diffusion correction was introduced for all NOESY
spectra.

137

The required correlation time was estimated using the measured

15

N relaxation rates for the

structured parts of the protein.
Structure calculations were performed within the standard ARIA protocol using PROLSQ

138

for

nonbonded parameters; 20000 and 40000 steps were used for the high-temperature (10000 K) torsion
angle simulated annealing (27 fs integration time) and the two Cartesian cooling phases (1000 K, 50 K as
the final temperatures, 3 fs integration time), respectively. Network anchoring was introduced into the first
three iterations of the protocol, and floating chirality was implemented for the prochiral moieties. A logharmonic potential

139

and the automatic restraints weight protocol were implemented during the second

cooling phase. During this stage, the weight for the dihedral restraints was reduced to 5, and hydrogen
bond restraints were introduced for those residues predicted by TALOS+

136

to be in a helical

conformation. RDCs for the helical fragments (excluding those from α I, residues 634−637) were
introduced as intervector projection angle restraints
HADDOCK software suite.
estimated using PALES

133

141

140

using the dipolar_segid.py script from the

The alignment tensor components necessary for the conversion were

and the measured RDC values on a preliminary NMR structural ensemble

37

obtained without RDC restraints. Those angular restraints limiting the torsional space by >25% were
introduced in the ARIA calculations starting from the fifth iteration. Of the 400 structures generated in this
way, 179 were refined with 24000 steps of a Cartesian dynamics protocol in explicit water.

142

Unless

specifically mentioned, default values were used for all ARIA input variables. The final structures were
analyzed using PRO-CHECK-NMR 2.0

143

and the WHATIF Web server.

144

Structures in the NMR

ensemble were aligned using the McLachlan algorithm as implemented in PROFIT version 3.1 and
visualized using open-source PyMOL version 1.7.6. The NMR ensemble has been deposited into the
Protein Data Bank (PDB) as entry 5KS5.
3.3.5 - Competition Assays
For the competition assays described below, eEF-2K was expressed and purified using protocols
described previously.
eEF-2,

146

36

Established procedures were utilized to purify wheat germ eEF-2

145

and yeast

for use in the peptide and eEF-2K627−725 inhibition assays, respectively. Wheat germ eEF-2

and yeast eEF-2

149

147,148

have been shown to be phosphorylated by mammalian eEF-2Ks with kinetic

parameters similar to the values of those derived from mammalian cells.
Competition assays were performed at 30 °C in buffer B [25 mM HEPES (pH 7.6), 2 mM DTT, 10
μg/mL BSA, 10 mM MgCl2, 100 μM EGTA, 150 μM CaCl2, and 2 μM CaM] at pH 7.6. For each
reaction, 10 μM eEF-2 was incubated with either 0 (25 mM HEPES) or 500 μM C-terminal peptide
(acetyl-707RLANQYYQKAEEAWAQMEE725-amide) for 30 min at 30 °C followed by incubation with 0.5
nM eEF-2K for an additional 10 min. The reaction was initiated by the addition of 1 mM [γ-32P] ATP
(100−1000 cpm/pmol) in a total volume of 100 μL. At set time points (60, 120, 180, 240, 300, and 360 s),
10 μL aliquots were taken and spotted onto P81 cellulose filters (Whatman, 2 cm × 2 cm). The filter
papers were then washed thrice in 50 mM phosphoric acid (15 min each wash) and once in acetone (15
min) and finally dried. The amount of labeled peptide associated with each paper was determined by
measuring the counts per minute on a Packard 1500 scintillation counter. All experiments were performed
in duplicate.
To test inhibition of eEF-2 phosphorylation by eEF- 2K627−725, eEF-2K (final concentration of 0.2
nM) was added to buffer B (pH 7.5, 6 μM eEF-2) containing either eEF- 2K627−725 (20 μM) or an

38

equivalent volume of buffer and equilibrated at 27 °C for 3 min, followed by initiation with 1 mM [γ-32P]
ATP, as described above. The reaction was allowed to proceed for 5 min, at which time 10 μL was
removed, added to quench buffer (5× SDS−PAGE buffer with 50 mM EDTA), and boiled for 5 min.
Quenched samples were subjected to SDS−PAGE analyses, and autoradiography images were acquired
using a Typhoon phosphorimager. Quantification of eEF-2 band intensities in the autoradiographs,
reported as arbitrary units, was conducted in ImageJ

150

after first linearizing the .gel file with the “Linearize

GelData” plug-in (https:// imagej.nih.gov/ij/plugins/linearize-gel-data.html). Additional quantification of
phosphate incorporated into eEF-2 was performed by scintillation counting of the excised eEF-2 bands
from the SDS−PAGE gel, using the specific activity of [γ-32P] ATP and the amount of eEF-2 per lane (60
pmol) to calculate the phosphate/eEF-2 molar ratio.
3.4 - Results and Discussion:
3.4.1 - Choice of the eEF-2K627−725 Construct
It has been previously reported, on the basis of sequence analysis, that the CTD of eEF-2K is
highly α-helical and is predicted to contain several SLRs.

48,51

To isolate, express, and structurally

characterize this region, we first attempted to localize the domain structure of the region by analyzing the
D473−E725 fragment of eEF-2K using bioinformatics tools. An analysis of the eEF-2K sequence against
the PFAM database

129

leads to the prediction of four SEL-1-like repeats (SLRs): L528−G562,

T590−D609, E636−M647, and A672−A699. Combining this prediction with the results of the GeneSilico
metaserver

151

to identify secondary structural elements and disordered regions, we designed the eEF-

2K627−725 construct to include the last two SLRs and the extreme C-terminus that has been shown to be
required for the phosphorylation of eEF-2.

48

3.4.2 - Resonance Assignment of eEF-2K627−725.
The

15

1

N− H HSQC spectrum of eEF-2K627−725 (Figure 4.2) shows dispersion that is characteristic

of high α-helical content and suggests the presence of well-ordered regions. Using standard backbonedirected triple-resonance experiments (see Table 4.1), we were able to assign all of the main chain amide
15

1

1

N, H, Hα,

13

Cα, and

13

C′ resonances for non-proline residues (excluding the four additional amino

39

1

acids remaining after thrombin cleavage). For the three prolines, all the Hα,

13

Cα, and

13

C’ resonances
1

could be assigned. Additionally, we obtained assignments for 100% and 99.5% of side chain H and

13

C

1

resonances, respectively; 92.4% and 84.3% of aromatic H and heteronuclear resonances, respectively,
1

were also assigned, and 88.9% and 84.2% of H and

15

N atoms belonging to the amino side chains of

Asn and Gln could be assigned, respectively. These assignments were then utilized to obtain distance
constraints from a variety of NOESY (Table 4.2) data sets and combined with chemical shift-based
backbone dihedral angle constraints using TALOS+

136

and

15

1

N− H RDCs to determine the structure of

eEF-2K627−725.
3.4.3 - Solution Structure of eEF-2K627−725.
As expected from chemical shift analysis, eEF-2K627−725 contains four helical segments. The structural
ensemble (Figure 4.3) confirms that these helical elements are localized to the regions encompassing (in
at least 90% of the structures comprising the NMR ensemble) W634−A637 (αI), R664−T677 (αII),
P686−E702 (αIII), and G706−Q722 (αIV). While helix αI comprises a single helical turn in all structures
of the NMR ensemble, this helical segment extends from D633 to W640 in ∼60% of the structures,
suggesting significant disorder at the extremities. Indeed, this helix appears to be more dynamic and
structurally ill-defined than the others (see below). In contrast, the last three helices are ordered and fold
into an antiparallel helical bundle, where individual helices (αII−αIV) stack sequentially on each other
and form an elongated shape centered on αIII. The overall fold is stabilized by a number of van der
Waals contacts involving contiguous helices, specifically between αII (involving residues Y665, L668,
A669, E671, A672, E673, L675, and F676) and αIII (R688, S689, L692, Y693, Q695, A696, A699, A700,
and A703) and between αIII (P686, Q687, G690, D691, Y693, T694, A696, A697, A700, and M701) and
αIV (L708, A709, Y712, Y713, K715, A716, A719, and W720). All of the listed residues participate in
multiple contacts, each detectable in at least 90% of the structures that comprise the NMR ensemble.
Further, a subset of these residues, namely, Y665, A669, and F676 on αII, Y693, A696, and A700 on α
III, and Y712 and A719 on αIV, stabilize the helical core by forming simultaneous contacts with both of
the other two helices of the bundle (Figure 4.4).
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Figure 4.2. Assigned

15

1

N, H HSQC spectrum of eEF-2K627-725 (600 MHz). Sidechain resonances are

labeled in red. Data were collected in a buffer containing 50 mM phosphate, 4 mM DTT at pH 6.5.
Experiments were performed at 25 °C.
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Figure 4.3. Structure of eEF-2K627−725. (A) The NMR ensemble consisting of the 20 lowest energy
structures overlaid on helices αII, αIII and αIV (using backbone heavy atoms). (B) Ribbon representation
of the lowest energy structure showing the location of the four helices. The helices (αII-αIV) that comprise
the helical core are shown in red and the N-terminal helix (αI) is shown in blue. Loops are shown in
green.
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As expected, from the root-mean-square deviation (RMSD values for the structures that comprise
the NMR ensemble (Table 4.3), the last three helices (αII−αIV) are largely ordered, displaying large
values for the reduced spectral density function at zero frequency, J(0) (2.6 ± 0.4 ns/rad), and small
values at high frequency, J(0.87ωH) (7.0 ± 1.3 ps/rad) (see Figure 4.5). The compactness of the tertiary
fold involving helices αII−αIV is the consequence of a large number (168) of long-range (≥i, i + 5)
contacts that leads to small pairwise rmsds among the structures (see Table 4.3) that constitute the NMR
ensemble. In contrast, this network of long-range contacts is missing for αI, and as a result, it assumes a
variety of different orientations with respect to the helical bundle in the NMR ensemble (Figure 4.3). That
this is indeed a true feature of this region of eEF-2K627−725 rather than an inadequacy in the NOE
assignment or in the structure calculation protocol is reinforced by the fact that the order parameters
predicted from the chemical shifts [RCI S2, (Figure 4.6A)]
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are lower for helix αI (0.73 ± 0.05) than for

the helical core comprising αII−αIV (0.87 ± 0.06). Additionally, αI is characterized by a J(0) (2.0 ± 0.3
ns/rad) lower than, and a J(0.87ωH) (12.7 ± 1.4 ps/rad) significantly higher than those of the αII−αIV
core, indicating a larger amount of disorder on the fast time scale (Figure 4.5). A plot of J(ωN) versus J(0)
shows that αI occupies a region distinct from the remaining helices (Figure 4.7). Further, while the amide
15

1

N− H RDC values for the helical bundle (αII−αIV) tend to be negative in sign and are generally quite

large in overall magnitude [−19 ± 10 Hz, (Figure 4.6B)], for helix αI, the RDC values range from −1.2 to
2.4 Hz and are not dissimilar from those observed in the contiguous, mostly unstructured Y641−Q660
loop (RDC = 1.6 ± 1.3 Hz). The RDC and relaxation data combined strongly suggest that αI is not
anchored to the helical core comprised of αII−αIV. This disorder is largely facilitated by the highly
dynamic nature of the αI−αII loop encompassing Y641−Q660 [J(0.87ωH) = 18.4 ± 3.5 ps/rad], and
indeed in the structures of the NMR ensemble, this region does not converge around a unique fold
(Figure 4.3). A statistical analysis of the secondary structure elements, however, indicates a propensity
for various turn like conformations in this area, as suggested by the presence of several medium-range
NOEs.
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Figure 4.4. Structure of the helical core, comprising helices αII-αIV. Residues that make key interhelical contacts are shown as sticks. Residues that stabilize the core by making contacts involving all
three helices are shown and labeled in red; other colors indicate helix-helix contacts as shown in the key.
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Table 4.3. Refinement and structure statistics for eEF-2K627-725
Pairwise Cartesian RMS deviation (Å)
All
Core
Global backbone heavy atoms
3.92 ± 2.12
0.93 ± 0.32
Global heavy atoms
4.56 ± 1.85
1.79 ± 0.32
Ordered backbone heavy atoms
1.18 ± 0.37
0.42 ± 0.10
Ordered heavy atoms
2.08 ± 0.41
1.41 ± 0.16
Restraint information
NOEs: Intra-residue
530
365
317
205
NOEs: Sequential (Δ=|i-j|=1)
221
174
NOEs: Medium (5 > Δ=|i-j| ≥2)
183
168
NOEs: Long (Δ=|i-j| ≥5)
122
98
Dihedral angle restraints (φ, ψ)
Inter-vector projection angle restraints
565
565
Hydrogen Bonds Restraints
70
68
Energies, NOE Statistics
-1
Total (KCal•mol )
-4313.72 ± 68.92
-1
Electrostatic (KCal•mol )
-4192.93 ± 70.1
-1
van Der Waals (KCal•mol )
-895.07 ± 10.1
Conformers NOEs RMS (Å)
0.167 ± 0.037
Ramachandran statistics (%)
Most favored regions
82.2
90.9
Additionally allowed regions
15.6
7.3
Generously allowed regions
1.1
1.8
Disallowed regions
1.1
0
Average RMS Z-scores for deviation from current reliable structures
Bond lengths
0.22 ± 0.01
0.20 ± 0.01
Bond angles
0.38 ± 0.01
0.33 ± 0.02
0.59
±
0.04
0.56 ± 0.06
Omega angle restraints (°)
Side-chain planarity
0.43 ± 0.12
0.46 ± 0.17
Improper dihedral distribution
0.45 ± 0.09
0.47 ± 0.13
Inside/Outside distribution
1.16 ± 0.03
1.06 ± 0.02
Average RMS Z-scores for deviation from current reliable structures
1st generation packing quality
-2.48 ± 0.15
-0.56 ± 0.18
2nd generation packing quality
-2.84 ± 0.38
-0.87 ± 0.39
-1.75 ± 0.73
-1.19 ± 0.69
χ1/χ2 rotamer normality
Backbone conformation
-0.86 ± 0.35
1.61 ± 0.25
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Figure 4.5. Spectral Density function of eEF-2K627−725. Reduced spectral density functions at 0 (A), ωN
(B) and 0.87ωH (C) frequencies calculated from backbone
25 °C are plotted against residue number.
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15

N relaxation data measured at 600 MHz and

2

Figure 4.6. Random Coil Index of eEF-2K627−725. Random Coil Index (RCI) derived S values (A) and
15

1

N- H residual dipolar couplings (RDCs) (B) measured using Pf1 phage for the eEF-2K627-725 construct

are plotted against residue number.
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Figure 4.7. Plot of the spectral density function at the

15

N frequency, J(ω N) against that at zero

frequency, J(0). The colored spheres represent data from specific regions of eEF-2K627-725 as follows –
green: αII, αIII, αIV and the αIII-αIV loop; red: αI; cyan: αII-αIII loop; yellow: αI-αII loop; blue: extreme Nand C-termini. The curve represents the limiting case where the protein is rigid without any internal
dynamics and molecular tumbling is characterized by a single correlation time (isotropic diffusion). Data
were collected at 600 MHz.
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3.4.4 - Similarities with Known Structural Families.
SLRs, together with the tetratricopeptide repeats (TPR) and the pentatricopeptide repeats (PPR),
form a class of proteins called solenoids.

153

Solenoids are comprised of basic repeating helix

(A)−turn−helix (B) motifs that stack onto each other forming a superhelical assembly driven largely by van
der Waals interactions connecting the second (B) and, to a lesser extent, the first (A) helix of a given
structural unit to the first helix (A’) belonging to the following repeat.
TPR, and PPR motifs

60

154,155

The structurally related SLR,

differ only slightly in their characteristic consensus sequences. In fact, SLR motifs
60

are considered to be a subclass of TPR motifs.

Compared to TPRs, SLRs are characterized by longer

loops between the two helices comprising the individual motifs and shorter loops connecting different
repeat units. The consensus sequences themselves, however, are loosely defined for TPRs and SLRs
alike, as they require few specific residues to be conserved, preferring instead broad classes of side
chains (small, large, hydrophobic, etc.) for the individual positions, and in fact, few positions are truly
invariant

156

(Figure 4.8). As a consequence, accurate sequence-based prediction of such entities in a

protein of unknown structure can be challenging.

157

Indeed, on the basis of the structure of eEF-2K627−725,

the length of the loop between αII and αIII (nine amino acids) is more consistent with an SLR rather
than a TPR. However, a query to the DALI server

158,159

for structures in the PDB homologous to eEF-

2K627−725 produces matches with a large number of motifs belonging to the TPR family but not the SLR
subfamily. While there is little difference between the structures of the individual repeats between the
canonical TPR and SLR motifs, the largest difference lies in their super helical parameters (resulting from
the arrangement of multiple repeats), with the former being narrower than the latter.

60

Therefore, whether

eEF-2K627−725 indeed conforms to a TPR motif or to an SLR motif can be confirmed only once the
structure of the intact CTD is available.
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Figure 4.8. Comparison of eEF-2K627−725 to TPR and SLR consensus motif. Sequence preferences for
the TPR and SLR consensus motifs (80% confidence) from SMART. Also shown at the bottom is the
sequence comprising the αII and αIII helices in eEF-2K627-725. Compare Figure 6 in the main text.
The SMART consensus group of residue types are as follows:
l (aliphatic): I, L, V
. (any)
a (aromatic): F, H, W, Y
h (hydrophobic): A, C, F, G, H, I, K, L, M, R, T, V, W, Y
p (polar): C, D, E, H, K, N, Q, R, S, T
s (small): A, C, D, G, N, P, S, T, V
u (tiny): A, G, S
t (turn-like): A, C, D, E, G, H, K, N, Q, R, S, T
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Superhelices of the TPR family often terminate with a single helical motif, termed the capping or
solubility helix that stabilizes the sequence. Upon analysis of the 10 best nonredundant entries that
resulted from the DALI query (see Table 4.4), we noted two distinct sets of patterns for the alignments
(Figure 4.9 and Table 4.4). In some of the cases, the αII−αIV helical core of eEF-2K627−725 aligns best
with a C- terminal repeat, with αIV aligning with the corresponding C- terminal capping helix. In others,
αII and αIII structurally align with a particular TPR hairpin in the matching protein while αIV aligns with
the (A) helix belonging to the following repeat module. Obviously, the first scenario appears to be the
more appropriate, given the C-terminal location of the eEF-2K627−725 fragment.
A structural alignment with an idealized TPR sequence is of interest because it allows the
comparison of side chain packing observed for eEF-2K627−725 to that of a structure derived from the
consensus sequence (Figure 4.10). Of the seven signature residues identified in the hairpin motif (in
addition to one in the intervening loop) by Main and co-workers,
A696) and three other positions are compatible with the SMART

155

two are fully conserved (Y693 and

160,161

consensus requirements (L668/W,

A672/G, L675/Y, and S689/A). The only side chain that appears to diverge from both the SMART and the
signature residue is found at position 671 (E671/L). In the idealized TPR structure, the signature residues
in a given helix form contacts with the complementary helix within the same hairpin, and with helices from
the neighboring repeats. E671 on αII is indeed involved in van der Waals interactions with αIII residues.
According to the TPR global propensities calculated by Main et al.,

155

the leucine residue in this position

(7 in their work, 10 in Figure 4.10A) has a propensity value much lower than those of the other signature
residues. The second highest propensity value for this side chain is an arginine, suggesting that charged
residues are tolerated at this position.
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Table 4.4. Structural Homologs of eEF-2K627-725
Count

PDB ID

CHAIN

Z

RMSD

% Identity

DESCRIPTION

1

2XCB

A

9.7

1.2

16

Regulatory protein PCRH

2

5A6C

B

9.4

1.3

5

G-protein-signaling modulator 2, Afadin

3

4A1S

A

9.1

1.2

7

Partner of Inscuteable

4

2VKJ

A

8.7

1.3

13

TM1634

5

1QQE

A

8.3

1.1

23

Vesicular transport protein SEC17

6

1TJC

A

8.1

1.9

13

Prolyl 4-hydroxylase alpha-1 subunit

7

2K3W

A

7.8

1.5

22

Vacuolar protein sorting-associating protein

8

4AIF

B

7.7

1.4

9

AH receptor-interacting protein

9

4BT8

A

7.7

2

11

Prolyl 4-hydroxylase subunit alpha-1

10

2IFU

C

7.5

1.5

23

Gamma-SNAP

The first two entries have been described in detail in the text.
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Figure 4.9. Comparison of the structures of the top two DALI matches with the αII-αIV helical core
of eEF-2K627-725 (green). The matched structures correspond to TPRs from the Pseudomonas
translocator chaperone PcrH (blue, Z=9.7), and human Afadin (orange, Z=9.4). Part of the Afadin
structure has been hidden for clarity in representation. In eEF-2K627-725, the αII-αIII fragment shows
excellent structural alignment with the last TPR of PcrH, with αII aligning with helix A and αIII aligning with
helix B of the helix(A)-loop-helix(B) motif. αIV corresponds to the C-terminal capping helix (Cap). For
Afadin, the αII-αIII fragment aligns with an internal TPR and αIV matches helix A’ for the following TPR
repeat, helix(A’)-loop-helix(B’).
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Figure 4.10. Comparison of eEF-2K627−725 to TPR motif. (A) Comparison of sequence preferences
(80% consensus) of the TPR motif predicted by SMART (top), the idealized TPR motif defined by Main et.
al

155

(middle) and the eEF-2K627-725 sequence (bottom). Conserved residue types are shaded purple;

E671 on eEF-2K627-725 that deviates from the large hydrophobic group expected at this position is shaded
red. The proline residue that is preferred at position 35 (shaded magenta) beyond the second helix, is
missing in eEF-2K627-725. For the PFAM preferences, h, t, u, a, p and s denote hydrophobic, turn-like, tiny,
aromatic, polar and small, respectively. Also see Figure 4.8. (B) Comparison between the structures of
the idealized TPR (left; the portion that aligns with αII and αIII on eEF-2K627-725 is shown in orange) and
eEF-2K627-725 (right; only helices II and III are shown). Key residues (colored light purple) from the
sequence comparison above are indicated. Similar residues are labeled in black; E671 (and the
corresponding L10) that deviates from the expected consensus residue type is labeled in red; helix αIII for
eEF-2K627-725 is longer by a turn than the idealized TPR; P35 (labeled in magenta) is missing in eEF2K627-725.
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As mentioned above, αI does not pack with the αII−αIV core; however, it contains a number of
aromatic and hydrophobic residues. This would suggest that αI likely corresponds to the second (B) helix
of the penultimate repeat, while the first (A) helix is not included within the boundaries of the eEF-2K627−725
construct. The lack of tertiary structure would indicate that the missing interactions with the first helix (A)
are required to stabilize the packing against the following repeat, and it is in fact likely that the boundaries
of helix αI itself will be different in the context of a fully formed domain. The loop between αI and αII
does not contain any defined secondary structure elements but does contain several hydro- phobic side
chains, so it is possible that this region could adopt different structural features in the context of the fulllength protein. Functional Role of the Extreme C-Terminus of eEF-2K. Next, we investigated whether the
structure of eEF-2K627−725 could be used to obtain insight into the mutational data of Pigott et al.

48

It was

shown that the deletion of the last 15 amino acids (711−725) is sufficient to abolish eEF-2
phosphorylation, with minimal effects on the phosphorylation of the MH-1 peptide. On the basis of the
structure of eEF- 2K627−725, deletion of the last 15 residues (Δ15) would result in the elimination of most of
the C-terminal capping helix (αIV) and, with it, multiple stabilizing interactions with the remaining helices,
most notably the interactions involving Y712, Y713, K715, A716, A719, and W720. Most importantly,
Y712 and, to some extent, the smaller A719 take part in multiple interactions with both αII and αIII and
stabilize the helical core (Figure 4.4). In contrast, deletion of the last eight residues (Δ8), and therefore
only of the smaller A719 but not of Y712, would be expected to have a much more modest effect, as is
seen.

48

For the Q711−E718 segment, the removal of which completely abolishes eEF-2 phosphorylation,

likely happens because the stabilizing interactions involving Y712 are eliminated. Pigott et al.

48

also

mutated several conserved residues in the 711−718 region of full-length eEF-2K to test for their effects on
eEF-2 phosphorylation. Mutation of each of the two highly conserved tyrosine residues (Y712 and Y713)
reduced the level of phosphorylation of eEF-2. In contrast, a Y712A/Y713A double mutation led to the
complete loss of the ability of eEF-2K to phosphorylate eEF-2. As in the case of the deletion mutants (Δ
15 and the 711−718 segment), none of these single or double mutations had comparable effects on the
ability to phosphorylate the MH-1 peptide. As described above, Y712 makes many hydrophobic contacts
within the helical core of eEF-2K627−725; therefore, its alteration would be expected to destabilize the three-

57

helix bundle to a greater extent than a Y713A mutation. Despite our best efforts, we failed to express the
Y712A mutant and test its structural characteristics by NMR. However, we successfully expressed the
Y713A mutant and found that the perturbations in the

15

1

N− H HSQC spectrum of this mutant when

compared to that of wild-type eEF-2K627−725, were small and largely localized near the site of the mutation
(Figure 4.11A). In contrast, the

15

1

N− H HSQC spectrum of the Y712A/Y713A double mutant reflected a

characteristic cigar shape expected in unfolded proteins (Figure 4.11B). Interestingly, another C-terminal
mutation, E717A, not only does not compromise eEF-2 phosphorylation but instead enhances the
capability of eEF-2K to phosphorylate both eEF-2 and MH-1.

48

In our NMR structure, E717 that is part of

the C-terminal helix (αIV) is largely exposed to solvent, and the E717A mutation does not appear to
affect the overall fold of this region (Figure 4.11C). As mentioned previously, the CTD of eEF-2K closely
162

associates with the KD and modulates its activity. A bioinformatics analysis

indicates that E717

coevolves with R200 on the KD, a residue predicted to be exposed in our previously reported homology
model of the KD.

127

This could indicate that a possible E717−R200 salt bridge provides a point of contact

between the CTD and the KD and that perhaps the E717A mutation alters the interface between the KD
and CTD, thereby modulating kinase activity. Finally, we performed a set of preliminary experiments to
test the suggested role of the CTD, specifically of its extreme C- terminus, in recognizing eEF-2. First, we
tested the ability of a 19-residue peptide (R707−E725) that encompasses the segment of residues
711−718 to inhibit eEF-2K-mediated phosphorylation of eEF-2. We found no difference in the rate of
phosphorylation of eEF-2 in the absence or presence of 500 μM peptide (Figure 4.12A). Curiously, not
only did the intact eEF-2K627−725 not provide any inhibition, its presence resulted in a slight increase
(∼14%) in the rate of phosphorylation of eEF-2 (Figure 4.12B). Additionally, a low level of phosphorylation
(data not shown) of eEF-2K627−725 itself was seen. This, as in the case of the E717A mutant, discussed
above, could be the result of a reorganization of the KD−CTD interface, due to intermolecular binding of
eEF-2K627−725 to the KD in competition with the intramolecular binding of the intact CTD (also underscored
by eEF-2K627−725 phosphorylation). These results, taken together, suggest that neither the linear sequence
encoded by the extreme C-terminus of eEF-2K nor the eEF-2K627−725 construct in isolation can efficiently
engage eEF-2.
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Figure 4.11. Comparison of

15

1

N, H HSQC spectra of eEF-2K627-725 mutants.

15

1

N, H HSQC spectra of

various eEF-2K627-725 mutants – Y713 (A), Y712A/Y713A (B) and E717A (C). The spectrum of wild-type
eEF-2K627-725 (blue) is shown in all cases for comparison.
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Figure 4.12. eEF-2K627-725 cannot outcompete eEF-2K for eEF-2 binding. (A) Phosphorylation of
wheat-germ eEF-2 (10 µM) by eEF-2K in the presence (squares) or absence (circles) of a 19-residue
peptide (R707-E725) that encompasses the 711-718 segment of eEF-2K. (B) Phosphorylation of yeast
eEF-2 (6 µM) by eEF-2K in the presence or absence of intact eEF-2K627-725 (20 µM). Top: Coomassiestained gel (upper panel) and autoradiography (lower panel) images of phosphorylated eEF-2 in the
presence (-) or absence (+) of intact eEF-2K627-725. Molecular weight marker (M) is also shown. Bottom:
quantification of eEF-2 phosphorylation by densitometry of the autoradiography image (left panel). The
amount of phosphate incorporated into eEF-2 by eEF-2K (reported as pmol phosphate/pmol eEF-2) was
quantified in the excised eEF-2 bands.

3.5 – Conclusion
Using NMR methodology, we have determined the solution structure of a 99-residue construct
(eEF-2K627−725) that encodes the extreme C-terminus of eEF-2K. The structure of eEF-2K627−725 reveals
that this region contains a three-helix core that is composed of a TPR-like motif capped by a C-terminal
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helix. The N-terminal end of the construct also contains a helix that is largely unstable and does not pack
against the C-terminal helical core. We expect that this helix is stabilized by additional interactions within
the intact CTD that are absent in the construct studied here. It is likely to be part of another, not yet
characterized, TPR-like motif. Further, the structure of this fragment provides a framework for interpreting
the functional data of Pigott et al.

48

that suggest that this region is required for the phosphorylation of

eEF-2. The structural fold of the C- terminal helical core of eEF-2K627−725, as well as the NMR spectra of
its Y712A/Y713A mutant, suggest that in the context of full-length eEF-2K this double mutation and the Δ
15 C-terminal truncation abolish eEF-2 phosphorylation by destabilizing the C-terminal capping helix and
compromising the structural integrity of the CTD. Thus, the lack of activity toward eEF-2 appears to be the
result of structural destabilization rather than a specific perturbation of a binding surface. Consistent with
these observations, neither a peptide that includes the region of residues 711−718 of eEF-2K nor the
eEF-2K627−725 construct in its entirety can interfere with the ability of full-length eEF-2K to phosphorylate
eEF-2. Thus, our data indicate that the major determinants for the eEF-2 recognition are not uniquely
contained within the last 15 residues of eEF-2K, as previously proposed.
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However, it is possible that the

engagement of the other parts of the CTD, and perhaps also of the KD, is required for eEF-2K627−725 (and
the segment of residues 711−718 therein) to attain the appropriate conformation to allow the binding of
eEF-2. Clearly, additional work, both structural and biochemical, is necessary to fully resolve this issue.
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Chapter 5 - Structural Dynamics of the Activation of Elongation Factor 2 Kinase by Ca Calmodulin
The contents of this chapter were published as:
2+

Will et al. Structural Dynamics of the Activation of Elongation Factor 2 Kinase by Ca -Calmodulin.
J. Mol Biol. in press (2018)
©

2018 Elsevier Ltd. (reproduced with permission)

5.1 Abstract
Eukaryotic elongation factor 2 kinase (eEF-2K), the only known calmodulin (CaM) activated
α−kinase, phosphorylates eukaryotic elongation factor 2 (eEF-2) on a specific threonine (Thr-56)
diminishing its affinity for the ribosome and reducing the rate of nascent chain elongation during
translation. Despite its critical cellular role, the precise mechanisms underlying the CaM-mediated
activation of eEF-2K remain poorly defined. Here, employing a minimal eEF-2K construct (TR) that
exhibits activity comparable to the wild-type enzyme and is fully activated by CaM in vitro and in cells, and
using a variety of complimentary biophysical techniques in combination with computational modeling, we
provide a structural mechanism by which CaM activates eEF-2K. Native mass analysis reveals that CaM,
with two bound Ca

2+

ions, forms a stoichiometric 1:1 complex with TR. Chemical crosslinking mass

spectrometry (XLMS) and small angle X-ray scattering (SAXS) measurements localize CaM near the Nlobe of the TR kinase domain and the spatially proximal C-terminal helical repeat. Hydrogen exchange
mass spectrometry (HXMS) and methyl NMR indicate that the conformational changes induced on TR by
the engagement of CaM are not localized, but are transmitted to remote regions that include the catalytic
center and the functionally important phosphate binding pocket. The structural insights obtained from the
present analyses, together with our previously published kinetics data, suggest that TR, and by inference,
wild-type eEF-2K, upon engaging CaM undergoes a conformational transition resulting in a state that is
primed to efficiently auto-phosphorylate on the primary activating T348 en route to full activation.
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5.2 Introduction
Elongation, the second of three broadly classified phases of translation

23,163,164

, is influenced by

three major protein factors in eukaryotes: elongation factor-1α (eEF-1α), elongation factor-2 (eEF-2) and
elongation factor-3 (eEF-3)

16,165

. While eEF-1α and eEF-3 are involved in recruiting aminoacyl-tRNAs to

the ribosome, eEF-2 is responsible for the GTP-dependent translocation of the nascent chain from the
ribosomal A-site to the P-site

16,17,165

. Addition of each new amino-acid residue to the elongating peptide

chain requires the hydrolysis of GTP by eEF-2, to generate the energy for translocation
Phosphorylation of eEF-2 on a specific threonine residue, Thr-56

31–34,58,167

166

.

, by eukaryotic elongation factor

2 kinase (eEF-2K) significantly reduces its affinity for the ribosome and results in an overall reduction in
rate of protein synthesis

18,32,168

. eEF-2K

34,58

is a member of the α-kinase family

169

that is largely unrelated

in sequence to canonical protein kinases. eEF-2 is the only validated physiological substrate of eEF-2K,
though other targets have recently been suggested

170

.
31,167

The kinase activity of eEF-2K is upregulated by its interactions with calmodulin (CaM)

,

making it the only known CaM-regulated α-kinase. However, this mode of activation contrasts that seen in
other CaM-dependent kinases e.g. CaM kinase II (CAMKII) that involve displacement of a regulatory
2+

“pseudo-substrate” segment from its kinase docking region upon Ca -CaM binding exposing critical
phosphorylation sites and the binding site for substrate

171,172

. This “release-of-inhibition” mechanism

55,71
37

appears not to be operative in eEF-2K, which utilizes a unique two-step allosteric activation mechanism .
Using comprehensive kinetic and biochemical techniques we have established that these steps are –
2+

(Step 1) the binding of Ca -CaM to eEF-2K resulting in a conformational change to generate a state that
enables efficient auto-phosphorylation on a primary activating threonine, T348

36,37

and (Step 2) the

engagement of the phosphorylated T348 by a phosphate binding pocket (PBP) on the kinase domain
leading to a further conformational change and resulting in a state with the highest activity towards the
substrate eEF-2. However, in the absence of structural information for full-length eEF-2K and for the
CaM•eEF-2K complex, the nature of the conformational transitions that facilitate these steps are not
known.
Several biochemical and truncation studies

37,49,51

have defined the domain organization of eEF-

2K (725 residues, 82.2 KDa), as shown schematically in Figure 5.1a. The N-terminus of eEF-2K

63

comprises of a non-canonical CaM-binding domain (CBD); we have recently determined the structure of
2+

53

this region bound to Ca -CaM(Figure 5.1b) . The structure of the catalytic kinase domain (KD) that
follows the CBD has been solved but the corresponding co-ordinates are not publicly available. The fact
that the eEF-2K KD shares significant overall sequence identity with other α-kinases
construction of a robust homology model (Figure 5.1b)

127

59,126

has allowed the

. Bridging the KD and the C-terminal region
60

(CTR; defined as the region between residues 490-725) that contains several α-helical repeats (HRs) , is
12

the regulatory loop (R-loop) that contains several positive and negative-regulatory phosphorylation sites ,
in addition to the aforementioned T348. We have determined the structures of two different C-terminal
constructs, CTR627-725 (this includes the final helical repeat, hence termed HR3)
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and CTR562-725 (that

includes the last two helical repeats, hence termed HR23; Piserchio et. al, in preparation). The HR23
construct (Figure 5.1b) represents approximately 70% of the CTR.
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Figure 5.1. eEF-2K Kinase Truncation (a) Schematic representation of the full-length (FL) and truncated
(TR) constructs of eEF-2K. TR is constructed by deleting 70 N-terminal residues and a section (359-489)
of the regulatory loop (R-loop) of FL. The N-terminal calmodulin-binding domain (CBD) and the kinase
domain (KD) are retained in TR, as are the C-terminal helical repeats (HR1, HR2 and HR3) along with the
primary activating phosphorylation site (T348). The deleted segment of the R-loop (359-489) is replaced
by a 6-glycine (G6) linker in TR. (b) The relevant modules for which validated structures are available are
shown. The KD including residues H103-P330 is a homology model (blue), the HR23 construct of the
2+

CTR (G562-E725, purple) and the Ca -CaM•CBD complex (CaM in light blue, CBD, S74-A100, in
orange) are NMR structures. The insets show the key residues (K205, R252 and T254) of the phosphate
binding pocket (PBP) on the KD and the 1-5-8 binding mode (W85, I89 and A92) of the CBD on CaM
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2+

(that contains 2 Ca ions at its N-lobe binding site; Ca
and C-termini of each module are indicated.
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2+

ions are absent from the C-lobe sites). The N-

As eEF-2K plays a critical role in modulating a central physiological process, protein translation, it
2+

is tightly regulated through multiple signals. These include its primary activation by Ca -CaM and higher
order regulation of activity by additional phosphorylation events mediated by kinases such as PKA
AMPK

174

6

, by pH and by cellular Ca

2+

levels

175

173

and

. However, a necessary first step towards understanding

this complex regulation of eEF-2K is to decipher in atomic detail the mechanism of its primary mode of
2+

activation that is mediated by Ca -CaM. Towards this goal, we developed a minimal construct of eEF-2K
that lacks 70 residues at the N-terminus and a section (358-489) of the R-loop (Figure 5.1a), but contains
both the primary activating auto-phosphorylation site (T348) and a second activating autophosphorylation site, S500, that has been shown to play a key role under basal Ca

2+

concentration

175

.

Here, we show that this construct, that we term the TR construct of eEF-2K (TR in short; 530 residues
2+

including the 6-glycine linker, 60.2 KDa), is similarly activated by Ca -CaM as full-length eEF-2K in vitro
and in cells. Further, we utilized a variety of mass spectrometric techniques including native mass
spectrometry, hydrogen exchange mass spectrometry (HXMS), chemical crosslinking mass spectrometry
(XLMS) together with solution NMR spectroscopy and small angle X-ray scattering (SAXS) to propose a
2+

structural mechanism by which Ca -CaM interacts with, and activates TR, and by inference, full-length
eEF-2K.
5.3 Results and Discussion
2+

5.3.1 TR forms a stable 1:1 complex with Ca -CaM
All studies described below (with the obvious exception of the functional studies in vitro and in
cells) have been performed using fully-dephosphorylated TR i.e. inactive TR. Therefore, in the present
manuscript, all the biophysical studies described below, probe events involved in Step 1 (described
above) to generate a conformation that enables efficient auto-phosphorylation on T348.
Since TR contains the primary CaM-binding region

53

(the CBD, Figure 5.1) of eEF-2K, we surmised that it

2+

would form a stoichiometric complex with Ca -CaM as in the case of full-length eEF-2K (FL). Indeed, TR
2+

forms a 1:1 complex with Ca -CaM as ascertained by size-exclusion chromatography (Figure 5.2) and
native electrospray ionization mass spectrometry (see below). In order to investigate the nature of the
2+

Ca -CaM•TR complex more quantitatively, we injected the eluate (Figure 5.3) from a size-exclusion LC

67

column directly into an electrospray ionization mass spectrometer for native mass analysis (SEC/ESIMS)

176

2+

. Ion peaks in the ESI-MS spectra of TR alone and in complex with Ca -CaM dominate the higher

m/z region of the mass spectra (Figure 5.4). The lower charge-density ions, centered around the +16
2+

charge state for TR alone and the +17 charge state for the Ca -CaM•TR complex, represent compact,
natively folded conformations. While both spectra also show the presence of higher charge-density ions
(shown enclosed by the red rectangles in Figure 5.4) due to partially disordered structures with significant
87

solvent accessibility , the relative abundance of these peaks is higher in the mass spectrum of TR alone
2+

(top panel in Figure 5.4a) in comparison to the spectrum of the Ca -CaM•TR complex (bottom panel in
Figure 5.4b). This is not surprising since the N-terminal CBD is likely to be disordered in the absence of
2+

Ca -CaM.

Figure 5.2. Gel filtration traces of Free and CaM bound TR. Gel filtration traces of TR (black) and the
2+

2+

Ca -CaM•TR complex (red; containing a slight excess of Ca -CaM) on a Hiload 16/60 Superdex 200
(GE HealthCare Biosciences) column pre-equilibrated with buffer containing 20 mM Tris, 200 mM NaCl, 2
mM DTT, 1 mM CaCl2 at pH 7.5. Note that the isolated 71-358 and 490-725 constructs in the absence of
the 6-glycine linker also form a stable complex. This linker was included in TR to reduce the number of
exposed N- and C-termini that could potentially complicate the cross-linking studies described in the text.
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Figure 5.3. In Line Gel filtration traces of Free and CaM bound TR for Native MS Analysis. TR (top
2+

2+

panel) or the Ca -CaM•TR complex (containing a slight excess of Ca -CaM; bottom panel) was injected
into a MAbPac SEC-1 size exclusion LC column pre-equilibrated with 50 mM ammonium acetate using a
flow rate of 50 µL per minute. The eluate was continuously monitored by a UV detector and injected
directly into a mass spectrometer for ESI-MS measurements. The arrows (purple for TR alone, green for
2+

2+

the Ca -CaM•TR complex and orange for Ca -CaM) indicate the start and end points of the elution time
range for which the ESI-MS data were averaged to generate Figure 5.4. The dotted vertical lines indicate
2+

the elution times corresponding to maxima of the A280 for TR and the Ca -CaM•TR complex.

2+

In addition to peaks corresponding to the 1:1 Ca -CaM•TR complex, charge states that
2+

correspond to Ca -CaM transiently dissociated from the complex were also observed. A close inspection
of these peaks reveals an isotopic distribution corresponding to CaM with 0, 1 and 2 bound Ca
none with 3 or 4 Ca

2+

2+

ions but

ions (see inset of Figure 5.4b and Figure 5.5). This is in line with the presence of
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only two Ca

2+

53

ions seen in the structure of CaM in complex with a peptide corresponding to the CBD . In
2+

contrast, free CaM, that was added in a slight excess to ensure the stability of the Ca -CaM•TR complex,
and that appears at a higher elution volume on the size exclusion column (Figure 5.3) reveals peaks
corresponding to 0, 1, 2, 3 and 4 bound Ca

2+

ions, as expected (Figure 5.5).

5.3.2 TR is active in vitro and in cells
Having confirmed the ability of TR to form a stoichiometric complex with CaM, we tested whether
2+

it retains the ability to be activated by Ca -CaM by measuring its efficiency in phosphorylating pep-S, an
efficient peptide substrate of FL

148

. No phosphorylated product was seen in the absence of CaM in a

2+

Ca -containing buffer (Figure 5.6a). However, pep-S was efficiently phosphorylated by TR upon the
inclusion of CaM with a kobs of 16.3±0.9 s

-1

compared with a kobs of 14.5±0.3 s
2+

-1

for FL (Figure 5.6b),

suggesting that the kinase activity of TR is stimulated by Ca -CaM to a similar extent as FL in vitro.
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2+

Figure 5.4. Native MS of eEF-2K TR and Ca -CaM• eEF-2K TR complex. ESI-MS analysis of free TR
2+

(a) and the Ca -CaM•TR complex (b) averaged over specific fractions eluted from a gel filtration column
(see Figure 5.3). Major charge states are labeled and states of higher charge corresponding to disordered
2+

regions (red rectangle) are also shown. For the Ca -CaM•TR complex shown in (b), charge states
corresponding to a minor population of a 2:2, rather than a 1:1, complex are labeled in blue. Also shown,
2+

2+

labeled in green, are the +7 and +8 charge states of free Ca -CaM dissociated from the Ca -CaM•TR
complex. The inset shows an expansion of the +7 charge state with the isotopic distributions resulting
from 0, 1 and 2 bound Ca

2+

ions. Also see Figure 5.5.
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Figure 5.5. Calcum Saturated CaM is Observable with Native MS.The top panel shows an expansion
2+

of m/z range corresponding to the +7 charge state of the CaM peak transiently dissociated from the Ca CaM•TR complex during ESI-MS (derived from the fractions between the green arrows in Figure 5.3; the
expanded spectrum is shown in Figure 5.4). The bottom panel shows a corresponding region for the free
CaM in solution (the region between the orange arrows in Figure 5.3) i.e. CaM that did not dissociate from
2+

2+

the Ca -CaM•TR complex during ESI-MS. The isotopic distributions in the spectra suggest that Ca 2+

CaM in the Ca -CaM•TR complex contains 2 Ca

2+

ions leading to peaks corresponding to 0, 1 and 2 ions

2+

(top panel). This contrasts free Ca -CaM that can bind upto 4 Ca
3 and 4 ions are seen on the bottom panel).
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2+

ions (peaks corresponding to 0, 1, 2,

To evaluate the behavior of TR in cells, vectors encoding either vector alone (CV), TR or FL were
-/-

transfected into MCF-10A (eEF-2K ) cells

37

that lack endogenous eEF-2K. While the cellular levels of TR

were found to be ~3-fold lower than that of FL (Figure 5.6C), the relative levels of eEF-2 phosphorylated
on Thr-56 were found to be comparable in the TR and FL transfected cells (Figure 5.6c, left panel). This
suggests that the activity of TR is significantly higher than that of FL in cells (Figure 5.6c, right panel).
This is not surprising since the negative regulatory phosphorylation sites on the R-loop e.g. S359 and
12

S366 (along with the positive regulatory site, S398) are missing in TR . Nevertheless, taken together with
2+

the in vitro data, our results suggest that TR retains its ability to be upregulated by Ca -CaM and to sitespecifically phosphorylate eEF-2 on Thr-56.
2+

5.3.3 Ca -CaM binding leads to greater solvent protection in specific regions of TR
We used hydrogen deuterium exchange mass spectrometry (HXMS) to estimate the extent of
2

solvent exposure of backbone amide positions in TR by measuring the degree of H incorporation upon
incubation with D2O for varying lengths of time (5, 10, 30 and 240 minutes). About 35% of the amide
2

protons of TR were replaced by H within the first 5 minutes of incubation. This was followed by slower
incorporation of an additional ~11% over four hours, suggesting that more than half the amide positions in
TR were well shielded from solvent (Figure 5.7). Absent a correction for back exchange, this number
represents a lower bound of the TR protons that are solvent-exchangeable over this timeframe. While
2+

HXMS data for the Ca -CaM•TR complex (MS analysis following 5, 10, 30, 60 and 240 minutes of
2+

incubation in D2O) revealed similar overall trends as for TR alone, the presence of Ca -CaM resulted in
increased overall protection (Figure 5.7). This decreased solvent accessibility can be attributed to
2+

increased steric shielding (due to Ca -CaM binding), decreased dynamics, or both.
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Figure 5.6. eEF-2K TR has the same activity as eEF-2K. (a) The activity (picomoles of product per
picomole of enzyme) of TR as ascertained through its ability to phosphorylate an optimal peptide
substrate (Pep-S) is stimulated by calmodulin (CaM) in the presence of Ca

2+

(red). TR cannot

phosphorylate Pep-S in the absence of CaM (green). (b) TR (blue) and FL (red) show similar activity
2+

towards Pep-S in the presence of Ca -CaM. The inset shows the kobs values, determined using the initial
rate regime, for the two cases. Each datum represents an average of duplicate measurements. (c)
-/-

Western blot analyses show lower levels of TR compared to FL in MCF-10A (eEF-2K ) cells following
transient transfection, but comparable levels of eEF-2 phosphorylated on Thr-56 (all measurements in
duplicate). eEF-2 levels in cells transfected with vector alone (CV), or in those expressing TR or FL, are
shown. Pan-actin is used as loading control. The right panel shows the relative activities of TR and FL (as
measured through Thr-56 phosphorylated eEF-2 levels; averaged over duplicate measurements)
normalized to the cellular levels of each construct.
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In order to determine the specific regions of TR that show increased protection in the presence of
2+

Ca -CaM, we relied on local HXMS measurements. TR in the apo state, or that in the context of the
2+

Ca -CaM•TR complex, was digested using an immobilized pepsin column after incubation in D2O for
varying lengths of time (5, 10, 30 and 60 minutes). The peptides generated were subjected to low
temperature HPLC-ESI-MS/MS analysis. In all, data for 196 overlapping peptides (representing 90.4%
coverage of the TR sequence; see Figure 5.8 for a representative dataset) could be analyzed. Of these, a
2+

total of 40 peptides displayed statistically significant increase in protection induced by Ca -CaM. None of
the peptides for which data could be analyzed showed a statistically significant decrease in protection in
2+

the presence of Ca -CaM. The largest overall increase in protection was seen in the β-barrel on the Nlobe of the KD including β2, β3, β4 and β5 (Figure 5.9). Increased protection was also seen on the
phosphate-binding P-loop and at the C-terminal end of αC, that along with the αD (that also shows
somewhat increased protection; see peptide 7 in Figure 5.9), constitutes the PBP, a pocket proposed to
accommodate phosphorylated T348, following its auto- phosphorylation.

Occupancy of the PBP by

phosphorylated T348 drives the second conformational transition (as part of Step 2, described above)
37

that facilitates the formation of the fully-active form of eEF-2K . Peptides corresponding to the αE helix
(peptide 8 in Figure 5.9) and the β5-αC loop (that connects the N-lobe β-barrel to αC; peptide 5) also
2+

showed increased protection in the presence of Ca -CaM.
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2+

2

Figure 5.7. Intact Mass HXMS of Ca -CaM•TR and Free TR. Representative bulk H uptake HXMS
2+

curves for TR alone (black) and the Ca -CaM•TR complex (red). The circles represent the experimental
data (5, 10, 30 and 240 minutes of D2O incubation for TR alone and 5, 10, 30, 60 and 240 minutes for the
2+

Ca -CaM•TR complex) and the solid lines represent multi-exponential fits through the experimental data
for visual guidance.
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2+

Figure 5.8. Local HXMS of Ca -CaM•TR and Free TR. Representative dataset illustrating the difference
2

2+

in H uptake in TR in the presence or absence of Ca -CaM. Each block represents a peptide and the four
rows for each peptide represent differences for the 5, 10, 30 and 60-minute datasets. Δ for a given
peptide is defined as follows:
!

Δ (%) = 100

!"#
𝐻!!"#
−
!

!

!"#
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!"#
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Where !𝐻!!"#
and !𝐻!!"#
represent H incorporation in the presence and absence of CaM for a given
2

peptide, respectively.

!

!"#
𝐻!"#
represents the maximum possible

2

H incorporation for that particular
2+

peptide. Δ > 0 (deeper shades of red) indicates greater protection in the presence of Ca -CaM. Important
loops, residues that correspond to the phosphate binding pocket (PBP) and key phosphorylation sites
(T348 and S500), are indicated. The glycines corresponding to the G6 linker that connects G358 to N490
2

are shown in larger font. The black arrows indicate peptides for which the H incorporation curves are
shown in Figures 4 and 5.
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Figure 5.9. CaM binding Increases protection of Kinase Domain from Hydrogen/Deuterium
Exchange. (a) Results of a representative HXMS dataset using a 60-minute D2O-incubation period
mapped onto the homology model of the KD of eEF-2K. Specific regions of the KD discussed in the text
are indicated. Each residue has been colored according to a Δav value (using a cyan to magenta gradient;
residues with no peptide coverage have been colored black) defined as:
!

Δ!" (%) = 100
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Where !𝐻!!"#
and !𝐻!!"#
represent H incorporation in the presence or the absence of CaM for a given
2

!"#
peptide and !𝐻!"#
represents the maximum possible H incorporation for that peptide. The <> denotes
2

an average over all peptides that contain a given residue e.g. in Figure 5.8, N77 is contained in 2
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peptides, W85 in 1 peptide, L104 in 7 peptides. Note that Δ > 0 indicates increased protection i.e. reduced
2

2

H incorporation in the presence of CaM. (b) Time-course of H incorporation for selected peptides that
2+

show statistically significant differences in the absence (black) and the presence (red) of Ca -CaM. The
data represent average and standard deviation values determined from three separate measurements.
The location of the peptides on the homology model of the KD are indicated using specific colors (the
2

corresponding colors are used in numbering the peptides on the H incorporation curves). Also shown on
the lowest panel (labeled as Ref) for comparison is a peptide for which no statistically significant change
in protection was seen. The bound ADP and sidechains of K132, E145 and K162 that have been shown
to cross-link with CaM are shown in stick representation and labeled.
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We have previously shown that the N-terminal CBD comprises the primary CaM binding region of
53

eEF-2K (and by inference, of TR) . However, a single peptide (77-86) that includes only one (W85) of the
critical CaM binding residues (CBD engages CaM in a 1-5-8 binding mode: W85-I89-A92; Figure 5.1b),
albeit the most important one, could be resolved in our local HXMS measurements (see Figure 5.8).
2+

While this peptide showed an overall trend suggesting increased protection in the presence of Ca -CaM,
the differences between the free and bound states were within the error bounds (not shown).
2+

Some parts of the CTR also showed statistically significant changes in protection upon Ca -CaM
binding. Increased protection was seen on three contiguous helices (α3’, α4’ and α5’; Figure 5.10)
belonging to the second (HR2) and third (HR3) helical repeats. Other regions of TR did not show any
2+

statistically significant changes in protection in the presence of Ca -CaM.
2+

5.3.4 Specific cross-links indicate the relative spatial location Ca -CaM and the structural
domains of TR
While the spatial organization of the structural domains of intact TR is unknown in the absence of
a three-dimensional structure, it is difficult to conceive that all of the regions that show increased
protection in the HXMS studies, discussed above, could simultaneously interact with CaM in the context
of a heterodimeric complex. For example, it seems unlikely that the N-lobe of the KD and the PBP could
both directly interact with CaM without large-scale distortions in the structures of TR, CaM, or both. Thus,
in order to parse the effects of direct interactions with CaM on the HXMS-determined solvent protection
from those that result from structural rearrangements within TR as a consequence of CaM-binding i.e.
long-range allosteric effects, we relied on the chemical cross-linking mass spectrometry (XLMS)
measurements

98,106

.
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Figure 5.10 CaM binding Increases protection of eEF-2K562-725 from Hydrogen/Deuterium
Exchange. (a) Δav values from a selected 60-minute dataset mapped onto a representative structure from
the NMR ensemble of HR23 construct using the same approach as in Figure 5.9. Only the region (G597E725) that is ordered in the NMR structure is shown. The coloring scheme is the same as in Figure 5.9A.
2

(b) H-incorporation time courses for peptides from the CTR that show statistically significant differences
2+

in the presence (red) and absence (black) of Ca -CaM. The location of the peptides on the HR23
structure are indicated using specific colors (the corresponding colors are used in numbering the peptides
2

on the H incorporation curves). The sidechain of K715 that cross-links with CaM is shown in stick
representation.
We utilized the “zero-length” carbodiimide cross-linker EDC that links primary amines (N-terminus
and lysine sidechains) to glutamate, aspartate sidechains and the C-terminus

177

. The cross-linked species

were digested with trypsin and the resulting peptides were analyzed using ESI-MS/MS. Several cross-
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linked peptides could be identified but only 7 could be localized to within segments on the interacting
partners (the KD and CTR of TR and CaM) that were short enough to be useful as constraints (see
Figures 3.15 and 3.16 for specific fragmentation patterns).
As shown in Table 5.1, a total of four inter-protein (Inter) cross-links between TR and CaM could
be identified, in addition to three inter-domain cross-links within TR (IntraTR) (Figure 5.11 and 4.*16). Of
the cross-links between CaM and TR, both ends of the cross-link (using a one-letter code for TR residues
and a three-letter code for CaM residues) could be uniquely identified for two - E145-Lys30 (Inter-2 in
Table 5.1) and K715-Glu87 (Inter-4 in Table 5.1). In addition, K132 and K162 on TR were identified as
forming cross-links with acidic residues on CaM (Inter-1 and Inter-3 in Table 5.1). It is notable that E145,
K132 and K162 are all localized on the N-lobe of the TR KD in regions that display increased protection in
2+

the presence of Ca -CaM (Figure 5.9) in the HXMS measurements.

Figure 5.11. Fragmentation pattern for the cross-links between CaM and TR listed in Table 5.1. U or
A imply unambiguous or ambiguous identification of cross-linked partners, respectively. For example, U/U
(Inter-4) signifies a situation where both cross-linked residues have been unambiguously identified. The
corresponding sequences are shown at the bottom of each panel and the cross-linked residues are
shown in red (peptide 1) and blue (peptide 2).
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Figure 5.12. The fragmentation patterns for inter-domain inter-domain (between the KD, CBD and
TR) cross-links within TR listed in Table 5.1. Labeling and coloring schemes are as in Figure 5.11.
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Table 5.1. List of cross-links between TR and CaM and between the domains of TR

Number
Inter-1

Inter-2

Peptide 1
117

YNAVTG
EWLDDEVL
IKMASQPF
GR140
141
GAMREC
FR148

Inter-3

151

Inter-4

708

KLSNFLH
AQQWK162

LANQYY
QKAEEAW
AQMEE725

IntraTR-1

87

IntraTR-2

509

IntraTR-3

HAIQKAK9
3

LNALDLE
KK517
517
KIGK520

Region
Peptide 2
Region
Cross-Links between TR and CaM
38
KD
SLGQNPTEA
CaM (N-lobe)
ELQDMINEVD
ADGNGTIDFPE
FLTMMAR74
22
KD
DGDGTITTKE CaM (N-lobe)
LGTVMRSLGQ
NPTEAELQDMI
NEVDADGNGT
IDFPEFLTMMA
R74
38
KD
SLGQNPTEA
CaM (N-lobe)
ELQDMINEVD
ADGNGTIDFPE
FLTMMARK75
87

CTR

EAFR90

CaM (C-lobe)

Cross-links between the domains of TR
685
CBD
DPQR688
CTR
CTR
CTR

248

DDNIR252

248

DDNIRLTPQ
AFSHFTFER265
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Crosslinked Residues
K132:Glu45/Glu47/Asp50

E145:Lys30

K162:Glu45/Glu47/Asp50

K715:Glu87

K93:D685

KD

K516/K517:D248

KD

K517/K520:D248/D249

2+

Given that the CBD, which is critical for the recognition of Ca -CaM, is located immediately Nterminal to the N-lobe of the KD, it stands to reason that CaM bound at the CBD is likely to be in physical
2+

proximity to the N-lobe of the KD and indeed poised to interact with it in the Ca -CaM•TR complex. Thus,
this increased protection seen for the N-lobe of the KD, in the HXMS studies described above, most likely
2+

results from a direct interaction with Ca -CaM. Indeed, our previous studies have indicated a somewhat
2+

reduced affinity of a peptide encoding only the CBD (KD ~245 nM) towards Ca -CaM compared to that of
53

full-length wild-type eEF-2K (KD ~17 nM) , suggesting that additional stabilizing contacts could exist
2+

2+

between Ca -CaM and eEF-2K. On the other hand, it is difficult to conceive of a scenario where Ca CaM engaged by the CBD and docked at the N-lobe of the KD could simultaneously interact with the
2+

PBP. Therefore, the increased protection seen at the PBP in the presence of Ca -CaM likely results from
a conformational change that is transmitted from the CaM docking site at the N-lobe of the KD as
explored in greater detail below.
The inter-domain cross-links within TR provide a means to assess the spatial locations of the
various domains of TR with respect to each other; the most useful amongst these is the unambiguous
K93-D685 crosslink (IntraTR-1 in Table 5.1) that places the C-terminal region of TR (specifically HR3)
close to the N-lobe of the KD. It is notable that K93 lies immediately C-terminal to residue 8 (A92; see
Figure 5.1b) of the CBD segment that engages CaM in a 1-5-8 binding mode. This would suggest that the
HR3 is also proximal to CaM, an arrangement that is supported by the observed cross-link between K715
and Glu87 (Inter-4 in Table 5.1). It is notable, however, that this region shows only a small increase in
2+

protection upon Ca -CaM binding in the HXMS measurements suggesting that while in spatial proximity
to CaM, it does not participate in a direct interaction with it, unlike the N-lobe of the KD.
Next, we tested the utility of the cross-links listed in Table 5.1 as inputs for the generation of a model of
2+

the Ca -CaM•TR complex using the homology model of eEF-2K KD

127

together with the NMR structures

2+

53

of HR23 construct (Piserchio et al., in preparation) and the Ca -CaM•CBD complex . First, we needed to
2+

assess whether the individual structures of the KD, HR23 and Ca -CaM•CBD complex (Figure 5.1b)
2+

were maintained in the context of the Ca -CaM•TR complex. We used a set of cross-links within the KD
and CTR modules of TR and within CaM itself to validate the structures. As evident from Table 5.2, the
2+

distances between residues found to be cross-linked in the context of the Ca -CaM•TR complex were

85

within reasonable distances of each other (generally < 23 Å)

178

in the structure of isolated HR23, and to a

large extent, for the homology model of the KD. This suggests that the structures of these modules are
2+

largely maintained in the context of the Ca -CaM•TR complex. The situation was drastically different for
2+

CaM, with the distances between cross-linked pairs calculated using the structure of the Ca -CaM•CBD
complex were found to be too large to allow efficient cross-linking if the structure were to be maintained.
This scenario is best embodied by the observed cross-link between Lys30 on the N-lobe of CaM with
2+

Glu127 on its C-lobe. These residues have a Cα-Cα distance of ~37 Å in the context of the Ca CaM•CBD complex, placing them at a distance that would not enable cross-linking. In contrast, the intraC-lobe distances between the cross-linked residues Lys94 and Glu127/Asp129 (Table 4) are far more
2+

reasonable at ~17-20 Å. These data suggest that the inter-lobe orientation in the Ca -CaM•TR complex
2+

is quite different from that represented in the Ca -CaM•CBD NMR ensemble. Given this scenario, it is not
surprising that while our efforts to model the KD•CTR496-725 complex (see Materials and Methods section
2+

for details) yielded converged structures (Figure 5.13), our attempts to include Ca -CaM•CBD in this
model did not lead to convergence.
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Table 5.2. List of cross-links within the domains of TR and within CaM
Residue 1

Residue 2

Cα-Cα Distance (Å)
TR

K150 (KD)

E174/D177 (KD)

24.0/24.6

K170 (KD)

D177 (KD)

13.7

K594 (CTR)

D629 (CTR)

11.5

K684 (CTR)

E717/E718/E725 (CTR)

16.1/14.2/14.0

a

a

CaM
Lys30 (N-lobe)

Glu127 (C-lobe)

36.6

b

Lys77 (C-lobe)

Glu31 (N-lobe)

26.1

b

Lys94 (C-lobe)

Glu127/Asp129 (C-lobe)

20.1/17.7

b

a

Average distance based on the NMR structural ensemble of eEF-2K562-725 (PDB: to be submitted)

b

Average distance based on the NMR structural ensemble of the Ca -CaM• eEF-2KCBD complex (PDB:

2+

5J8H)
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As shown in Figure 5.14, the structural model for the KD•CTR496-725 complex is consistent with all
the observed inter-domain crosslinks within TR. Indeed, the model is also consistent with the crosslinks
with segments of TR that were not explicitly included in the model itself e.g. it is completely plausible for
D685, that is spatially proximal to the N-terminus, to cross-link with K93, a part of the N-terminal CBD
(Figure 5.1b), that is not represented in the model. This suggests that the computational model
2+

represents a plausible organization of the domains of TR in the context of the Ca -CaM•TR complex.
While this analysis does not provide a structural model for CaM within the complex, the locations of K132,
E145, K162 and K715, all of which cross-link with CaM (Figure 5.14b), suggest a spatial localization of
CaM near the N-lobe of the KD and the C-terminus of the CTR near HR3.
2+

5.3.5 Ca -CaM binding leads to allosteric effects in the TR kinase domain
For the computational model described above, there are regions of TR that show increased
2+

protection from solvent in the presence of Ca -CaM in the HXMS studies but are not found to be spatially
proximal to it (Figure 5.14c). These regions include the PBP and parts of the CTR in which increased
protection from solvent likely results from conformational changes that result upon the engagement of the
2+

CBD and the N-lobe of the KD by Ca -CaM. For an additional orthogonal test of this hypothesis, we
utilized methyl TROSY NMR spectroscopy using the δ1 positions of the 20 Ile residues of TR
δ1 resonances were assigned by comparison of

13

1

C, H SOFAST-HMQC

180

179

. The Ile

spectra of wild-type

13

1

C, H-

Ile-δ1-labeled TR with corresponding spectra of point mutants where a particular Ile was replaced by Leu
(except I232A and I522S). Using this approach 15/20 Ile-δ1 resonances were unambiguously assigned
(Figure 5.16). Resonances corresponding to I89 and I349 could not be uniquely identified but were
attributed to a single cluster along with I237. I131 and I215 are proximal in space on the N-lobe of the KD
and mutation of one altered the resonance position of the other, though this exercise allowed narrowing
down the corresponding assignments to a pair of well-resolved resonances.
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Figure 5.13. Plot of the interface score of the final structures of the KD•CTR496-725 complex. Plot of
the interface score in Rosetta Energy Units (REU) of the final cluster of 264 structures of the KD•CTR496725

complex against the interface root mean squared deviation (RMSD) from the best scoring decoy

(shown in Figure 5.14). Structures with acceptable interface energies (-5 REU or lower) center around
three distinct interfaces that are within ~4, ~14, or ~17 Å from the reference decoy. The lowest point in
each cluster represents a local minimum in the energy landscape, decoys that center around it also score
consistently within the acceptable range. The cluster with RMSD values ranging from 0 to 4 Å contains
the decoys with the best interaction energies and represents the deepest well in the interaction energy
landscape. Decoys from this cluster were accepted to be representative of the global minimum.
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Figure 5.14. Structural Model of the eEF-2K Kinase Domain in Complex with eEF-2K490-725. (a)
Computational model of the KD•CTR496-725 complex using a homology model of the KD (shown in blue),
the NMR structure of CTR597-725 (extracted from HR23, shown in purple); the structure of the remaining
fragment has been modelled using Rosetta (shown in grey). The N- and C-termini of each fragment are
labeled. (b) Sidechains of the residues that form cross-links between the KD and the CTR (IntraTR-2 and
IntraTR-3 in Table 5.1) are shown in stick representation. Sidechains of cross-linked residues are shown
red (peptide 1) and cyan (peptide 2), respectively. These cross-links were used as constraints in
generating the model for the KD•CTR496-725 complex. Note that D685 (shown in blue) cross-links (IntraTR1 in Table 5.1) with the N-terminal K93 (that belongs to the CBD, in orange) that is not part of the model.
Sidechains of residues that cross-link with CaM listed in Table 5.1 are shown and labeled in magenta. (c)
Locations of the peptides that show statistically significant differences in protection in the HXMS
2+

measurements in the presence of Ca -CaM are colored red (peptides 1-8 from Figure 5.9 and peptides
1-3 in Figure 5.10).
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2+

As expected, several Ile resonances showed significant perturbations in the presence of Ca CaM (Figure 5.15a). These include I131 and I215, located on the N-lobe of the KD, as well as I251, I271,
and I275 all of which lie at or near the PBP. Resonances corresponding to residues I209, I232 and I287,
that lie near the catalytic site, are not identifiable in the bound form (most likely due to extremely large
chemical shift changes), suggesting substantial conformational rearrangements at the catalytic center. An
inspection of Figure 5.15b reveals that the perturbed Ile residues form a connected network extending
from the N-lobe of the KD to the PBP. This indicates a likely pathway by which conformational changes
2+

induced by the engagement of the N-lobe of the KD by Ca -CaM could be transmitted to remote sites
including the PBP. The likely existence of this long-distance communication network is underscored by
37

the fact that a T348A mutation leads to a ~10-fold decrease in the affinity of eEF-2K for CaM . In contrast
to the KD, most of the Ile residues on the CTR are not located in regions that show significant protection
2+

in the presence of Ca -CaM (Figure 5.16) in the HXMS measurements. The resonance corresponding to
I614, that lies in this region, does show some broadening but this perturbation is not as significant as that
seen for the KD resonances.
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Figure 5.15. CaM Binding Induces Chemical Shifts of Ile methyl groups across both lobes of the
eEF-2K Kinase Domain. (a)

13

1

C, H HMQC spectra (800 MHz) of

13

1

2

C, H-Ile-δ1, H-labeled TR in the

2+

absence (green) or presence (magenta) of CaM in a Ca -containing buffer. The resonances that show
significant perturbations are labeled in blue. The resonances corresponding to the spatially contiguous
I131 and I215 (enclosed by the black rectangle) that could not be uniquely assigned yet are both
perturbed (one disappears and the other shows a significant change in resonance position) are labeled
using light blue lettering. (b) The spatial distribution of the perturbed residues is indicated on the
homology model of the KD using spheres, colored and labeled using the same scheme as in (a).

Figure 5.16. Assigned

13

1

C, H-Ile-δ1 HMQC and the Distribution of Ile Residues on the Model of the

KD•CTR496-725 Complex. The left panel illustrates a

13

1

C, H HMQC spectra (800 MHz) of

13

1

2

C, H-Ile-δ1, H-

2+

labeled TR in a Ca -containing buffer with the resonances labeled with their corresponding assignments.
The resonances corresponding to the spatially contiguous I131 and I215 (enclosed by the green
rectangle and labeled in green) could not be uniquely assigned. I89, I349 and I237 belong to a single
unresolved cluster as do I522 and I614. The right panel shows the distribution of Ile residues on the
model of the KD•CTR496-725 complex. The colors of the labels are the same as in the left panel. I89 (CBD)
and I349 (R-loop) that are labeled in orange and grey, respectively, are not present in the model. I317
2+

(labeled in cyan) that lies in the Zn -. Locations of the peptides that show statistically significant
2+

differences in protection in the HXMS measurements in the presence of Ca -CaM are colored red as in
Figure 5.14c.
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2+

5.3.6 SAXS measurements suggest an elongated structure for the Ca -CaM•TR complex
2+

We used small angle X-ray scattering to determine the overall hydrodynamic features of the Ca CaM•TR complex. The complex showed no signs of aggregation over more than a 3-fold range of
concentration (from 1.9 mg/mL to 6.4 mg/mL; Figure 5.17a). This contrasts the behavior of TR alone that
showed significant aggregation at moderate-to-high concentration (Figure 5.18). An analysis of the SAXS
data using GNOM

181

within the ATSAS suite

182

produced a radius of gyration (RG, see Table 5.3 for

details) of ~37 Å and Dmax of ~130 Å (Figure 5.17b). The expected RG value for a globular species of the
2+

same number of amino-acid residues as the Ca -CaM•TR complex is expected to be roughly 26 Å

183

,

suggesting that the complex forms an elongated structure in solution. This is also borne out by the
molecular envelope calculated from the SAXS data that suggests a species that is approximately 130 Å
by 92 Å by 34 Å in solution (Figure 5.17c). Using the modeled structure of the KD•CTR496-725 complex
2+

(described above) in addition to that of Ca -CaM•CBD tethered to the N-terminus of the KD using a
flexible linker, we used CORAL

182

in combination with the 6.4 mg/mL SAXS data to model a structure of

2+

the Ca -CaM•TR complex without the use of any additional constraints. As shown in Figure 5.17c, the
model shows CaM localized near the N-lobe of the KD and the C-terminal end of CTR. In addition, the
various structural modules are accommodated well into the SAXS-determined molecular envelope. It is
2+

interesting to note that even when we did not tether the Ca -CaM•CBD module to the N-terminal region
of the KD using a flexible linker during the CORAL

182

calculations, there was little variation in the N-

terminal localization of the former, in agreement with the cross-linking data discussed above. Thus, TR
2+

forms a hatchet-shaped complex with Ca -CaM, the former comprising the blade and the latter, the
handle, as shown in Figure 5.17c.
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2+

Figure 5.17. SAXS Analysis of CaM Bound eEF2K TR. (a) Plot of the SAXS data of the Ca -CaM•TR
complex at two different concentrations, 1.9 mg/mL (red) and 6.4 mg/mL (blue). The data have not been
normalized with respect to concentration. The corresponding Guinier regions are shown in the inset. (b)
Concentration normalized pair distribution functions for the SAXS data from (a). (c) The hatchet shaped
molecular envelope generated from the SAXS data for the 6.4 mg/mL sample showing the approximate
dimensions based on the diameters along the three principal axes of the inertia tensor calculated using
UCSF Chimera. The spatial locations of CaM (light blue), CBD (orange), KD (dark blue) and CTR496-725
2

(purple) in the context of the KD•CTR496-725 complex determined using CORAL (χ =1.52) are shown.
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Figure 5.18. Concentration-scaled SAXS curves for apo TR at three different concentrations. The
deviation between the three curves at low q values (indicated by the green dashed oval) suggests
concentration dependent aggregation. The I0/c values were 1.30±0.02, 1.69±0.02, 2.16±0.03 for
concentrations of 3 mg/mL, 5 mg/mL and 10 mg/mL, respectively. The corresponding RG values were
45.7±1.2 Å, 55.0±1.2 Å, 64.9±1.2 Å.
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2+

Table 5.3. Results of SAXS analysis on the Ca -CaM•TR complex
Concentration (mg/mL)

1.9
Guinier Analysis

6.4

I0/c

1.34±0.01

RG (Å)

35.5±0.4

qmin

0.01234

qmaxRG

1.26±0.00
34.7±0.4
0.01665

1.25
Molecular Mass Analysis (Da)

MW from QP (qmax)
MW from Vc (Vc; qmax)
Bayesian credibility interval (MW)

1.27

76955 (0.1971)

74302 (0.2185)

68580 (548; 0.3011)
67900-75300 (72400)

66871 (534;0.3011)
69650-75300 (72400)

P(r) Analysis
RG (Å)

37.45±1.36

36.53±1.29

Dmax (Å)

130

128

q range

0.0195-0.2250

0.0238-0.2293

χ

2

0.8294
DAMMIF (20 runs, default parameters)

q range

0.0195-0.2250

Symmetry/anisometry

P1/unknown

NSD
2
χ range

1.384±0.183

Resolution from SASRES (Å)
MM (0.5×volume) (Da)
q range
χ

2

0.765-0.767
42±3
69140±390
DAMMIN
0.0195-0.2250
0.7928

0.8360
0.0238-0.2293
P1/unknown
1.166±0.113
0.971-0.977
37±3
66870±315
0.0238-0.2293
0.9723
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5.4 Conclusions
We have developed a minimal construct of eEF-2K lacking a significant segment of its N-terminus
and most of the regulatory R-loop linking the kinase domain to the C-terminal region. The presence of the
N-terminal CaM-binding domain and the section of the regulatory loop including T348, the site of primary
2+

activating auto-phosphorylation, ensures that this minimal construct (TR) is activated by Ca -CaM to a
similar extent as full-length enzyme in vitro while retaining its ability to efficiently phosphorylate eEF-2 on
Thr-56 in cells.

Analysis of chemical crosslinking data using mass spectrometry and computational

modeling suggest a topology for TR in which the C-terminus of the CTR (HR3) is spatially proximal to the
2+

N-lobe of the KD, and where both of these regions lie in close proximity to CaM in the Ca -CaM•TR
2

complex. Increased protection against H exchange with solvent in HXMS studies suggests that CaM,
that is anchored to its primary binding site at the N-terminal CBD, is likely stabilized further by additional
interactions with the N-lobe of the KD. The importance of these latter interactions is also borne out by the
2+

fact that the affinity of Ca -CaM towards a peptide encoding the CBD is ~15-fold lower than that
compared to full-length eEF-2K. It is also notable that an affinity of ~1 µM remains even upon mutation of
53

the key CaM-anchor residue on the CBD (W85S) . A preponderance of validated cross-links between the
N-lobe of CaM (3 of 4 cross-links with TR involve the N-lobe of CaM; see Table 5.1) and the TR KD
seems to suggest that the N-lobe of CaM is more proximal to TR than the CaM C-lobe. Though additional
data are needed to confirm this hypothesis.
It is noteworthy that regulatory interactions involving the N-lobe of the kinase domain are not
2+

unprecedented in α-kinases. The KD of the Ca -dependent TRP channel is active as a head-to-head
domain swapped dimer that forms through the interactions of an N-terminal helical segment of one
protomer that packs against the αC helix of the second (Figure 5.19)

126

. This interaction involves

significant contacts between the N-lobe β-barrel regions of the two protomers. Truncation/deletion of this
N-terminal segment or mutation of specific residues therein leads to loss of dimerization or kinase activity
or both.

184

It has been previously proposed that the N-terminal CBD of eEF-2K could play a similar role,

with CaM perhaps substituting for the second protomer

184

in activating the enzyme.

The established view for the activation of CaM-regulated kinases is the so-called “release of
inhibition” mechanism

172

in which the active site is blocked by a “pseudo-substrate” moiety that also
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2+

contains a CaM recognition element; engaging Ca -CaM releases this inhibition and allows kinase
activation. As mentioned previously, eEF-2K appears to be activated by a different mechanism. It has
been shown by Tavares et al.

37

2+

that the presence of Ca -CaM has a drastic effect on the intrinsic

catalytic activity (>2000-fold increase in kcat) without major changes in the affinity for a peptide substrate
(~2-fold decrease in the apparent KM) and a decrease in the affinity for ATP (~8-fold increase in the
apparent KM). Our HXMS results are indeed consistent with these data with no decrease in solvent
2+

protection seen at the catalytic cleft of TR (or for that matter, for any other region) upon engaging Ca CaM. The HXMS data that shows increased protection in regions on the KD that are well separated in
space including on the PBP and indeed on the regions of the CTR that are spatially proximal to the kinase
2+

active site in our computational model, suggest significant conformational changes in TR upon Ca -CaM
binding. These data are in line with the NMR analysis that reveals spectral perturbations spreading
2+

across most of the KD in the presence of Ca -CaM. We suspect that this set of conformational changes,
that enhances the intrinsic catalytic activity of eEF-2K, represents the first of the two conformational steps
37

in its activation pathway predicted in the kinetics studies of Tavares et al. . This change likely involves a
remodeling of the catalytic cleft, enabled by a series of conformational transitions propagating from the Nlobe of the KD, the site of engagement with CaM, as suggested by our NMR analysis. This remodeling is
perhaps also facilitated by a rearrangement of the relative positions of the KD and CTR. The role of the
CTR in modulating the activity of eEF-2K is highlighted by the previous observation that the isolated KD is
incapable of phosphorylating not only eEF-2, but also a substrate peptide. However, this ability can be
restored in trans by the CTR.

48

2+

Our studies also highlight the fact that Ca -CaM binding induces greater

order at the PBP. This change could be perceived as a conformational rearrangement in preparation to
accommodate phosphorylated T348 leading to the second conformational transition predicted in the
kinetics studies resulting in a state with the highest activity towards substrate.

37

While our current studies

provide insight into the overall organization of the structural domains of TR and of CaM in the context of
2+

the Ca -CaM•TR complex and evidence of significant conformational changes (Figure 5.20) induced by
2+

Ca -CaM binding to TR priming it to enable efficient auto-phosphorylation on T348, the precise nature of
these transitions await high resolution structures of the complex and more detailed analyses of dynamics
using NMR and/or computational approaches. In this regard, the stripped-down yet functional TR

98

construct provides an added benefit for future structural studies - since it is missing many of the segments
that are expected to be disordered in full-length eEF-2K, it could, in principle, be an excellent candidate
for crystallization trials. Our extensive efforts to obtain crystals of full-length eEF-2K have not yielded any
positive results. Further, the smaller size of TR (60 kDa) should also ease the performance of detailed
NMR analyses that would have been more problematic in full-length eEF-2K (82 kDa).
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2+

Figure 5.19. The dimeric structure of the C-terminal α-kinase domain of the Ca -dependent
transient receptor potential (TRP) channel, ChaK (PDB: 1IAJ). The two protomers that form a headhead domain-swapped dimer through the exchange of an N-terminal helix, are colored red and blue, and
shown in ribbon and surface representations.
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We note that the current studies probe events involved with Step 1 of the two-step activation
process of eEF-2K. Thus, our analyses are sensitive to all conformational changes following the
2+

engagement of Ca -CaM that lead to a state capable of efficiently auto-phosphorylating on T348. An
additional set of conformational transitions are expected after T348 phosphorylation and engagement of
the PBP by phospho-T348

37

(Step 2). These latter events will be probed by future studies on T348-

phosphorylated TR.
5.5 Materials and Methods
5.5.1 Expression and purification of His6-SUMO-tagged TR
A His6-SUMO tagged TR construct was cloned into a pET15b expression vector (Novagen) between the
NdeI and BamHI restriction sites and transformed into BL21 DE3 E. coli cells (New England Biolabs) for
expression. The cells were plated on ampicillin plates and incubated overnight at 37 °C. A single colony
was inoculated into 10 mL of LB medium (containing 100 mg/L of ampicillin) and grown overnight at 37
°C. The overnight culture was inoculated into 0.4 L of LB medium and grown at 37 °C until the culture
reached an A600 of 0.8, at which point the temperature was reduced to 18 °C and expression was induced
by the addition of IPTG to a final concentration of 0.4 mM. Post induction, the cells were grown for 16
hours and harvested by centrifugation at 2820 × g for 30 minutes. The cell pellet was re-suspended in 50
mL of cold lysis buffer (20 mM Tris, 200mM NaCl, 0.1% β-mercaptoethanol, 0.1% Triton X-100, 10 mM
imidazole and 1 tablet of Roche Complete Mini EDTA-free inhibitor tablet, at pH 7.5); all subsequent
steps described below were carried out at 4 °C. The cells were lysed by sonication and cell debris was
removed by centrifugation at 10800 × g for 30 minutes. The soluble lysate was added to a 5 mL (bed
volume) Ni-NTA affinity column (Qiagen) previously equilibrated with lysis buffer and incubated for 1 hour
with end-over-end rotation. The column was then washed extensively with washing buffer (20 mM Tris,
200 mM NaCl, 0.1% β-mercaptoethanol, 20 mM imidazole, pH 7.5) and the bound protein was
subsequently eluted with 50 mL of elution buffer (20 mM Tris, 200mM NaCl, 0.1% β-mercaptoethanol,
250 mM imidazole, pH 7.5). The His6-SUMO tag was cleaved by the addition of ULP1 protease (1ug per
50 mL of elution) and dephosphorylated with λ-phosphatase (New England Biolabs) during overnight
dialysis into cleavage buffer (20 mM Tris, 200 mM NaCl, 0.1% β–mercaptoethanol, 1 mM MnCl2, pH 7.5).
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The effectiveness of cleavage was monitored by 12% SDS-PAGE gels. The cleavage reaction was
quenched by addition of 0.1 mM AEBSF. The cleaved protein was further purified via ion exchange
chromatography using a 5 mL Hitrap Q HP column (GE Life Sciences) applying a linear NaCl gradient
from 0.2 to 0.8 M in a buffer containing 20 mM Tris, 2 mM DTT at pH 7.5. The purified protein was then
concentrated using spin columns and further purified by gel filtration chromatography using a Superdex
200 10/300 GL (GE HealthCare Biosciences) column pre-equilibrated with a buffer containing 20 mM
Tris, 200 mM NaCl, 2 mM DTT, 1 mM CaCl2 at pH 7.5 (referred to as SEC buffer).

Figure 5.20. Model of CaM Mediated eEF-2K Activation. A model for Step 1 of the two-step activation
2+

22

2+

of eEF-2K by Ca -CaM is shown schematically. The CBD (orange) is engaged by Ca -CaM (light blue)
with the loss of 2 Ca

2+

ions (from the C-lobe of CaM). This primary interaction is supplemented by

additional weak interactions of CaM (most likely through the CaM N-lobe) with the N-lobe of KD (blue).
The docking interaction between CaM and the eEF-2K KD leads to conformational changes that are
transmitted to remote sites on the latter (represented schematically by the yellow dashed arrows)
including the phosphate binding pocket (PBP, cyan), the catalytic center (grey oval) and the CTR (purple).
This results in a conformation (extreme right) that is primed to efficiently phosphorylate on T348 (yellow
2+

with black outline). Thus, Ca -CaM binding to eEF-2K may be conceived as leading to the formation of a

102

transient “excited-state” configuration of the binary complex that subsequently relaxes to a stable prechemistry complex primed to efficiently phosphorylate on T348.
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2+

Calmodulin was expressed and purified as described previously . To generate the Ca -CaM•TR
complex, purified CaM in a SEC buffer was added to the TR samples in the same buffer in a 1:2 molar
2+

ratio followed by gel filtration (as above) to purify the 1:1 complex. Fractions containing the pure Ca CaM•TR heterodimer were collected and concentrated using spin columns to final concentrations ranging
from 40 to 50 µM for hydrogen exchange mass spectrometry and chemical crosslinking experiments.
5.5.2 Analysis of TR activity in vitro
Measurement eEF-2K activity against a peptide substrate (Pep-S) was carried out as described
previously, in the following buffer: 25 mM HEPES, pH 7.5; 2 mM DTT; 10 µg/mL BSA; 50 mM KCl; 10 mM
32

MgCl2; 100 µM EGTA; 150 µM CaCl2; 2 µM CaM; 150 µM Pep-S; 1.0 mM [γ- P]-ATP; and 2.5 nM eEF2K G6. Calmodulin was omitted from this buffer for assays in the absence of CaM

36,54

. All experiments

were performed in duplicate.
5.5.3 Generation of the TR-pcDNA3-HA-FLAG construct
Overlap-extension mutagenesis was used to directly generate TR starting with the wild-type eEF37

2K-pcDNA3-HAF construct described previously . Primers were designed to incorporate ends
compatible with ligation-independent cloning (LIC). The mutagenesis product and amplified pcDNA3-HAF
vector were digested with T4 DNA polymerase in the presence of dATP or dTTP, respectively. The
digested products were annealed at room temperature and transformed into DH5α, purified, and
sequenced.
-/-

5.5.4 Analysis of TR activity in MCF-10A eEF-2K cells
-/- 37

MCF-10A cells lacking endogenous eEF-2K (eEF-2K )

were plated at a density of 150,000 cells

per well in 6-well tissue culture plates. The following day, cells were transfected using Lipofectamine
3000, according to the manufacturer’s instruction (using 2 µL P3000 reagent per µg DNA, and 2.5 µg
DNA per well), with pcDNA3-HAF vectors encoding either wild-type eEF-2K or TR, or an empty control
vector (CV). Transfection was carried out for 6 hours in DMEM/F12 lacking any supplements, after which
time the media was changed to complete MCF-10A media. Cells were then allowed to recover for 48
hours to allow for expression prior to lysis. Lysis and Western blotting for eEF-2K activity were carried out
37

as described previously . The following primary antibodies were used:
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eEF-2

p-Thr56

, #2331, Cell

Signaling Technologies (diluted 1:2000); eEF-2, Millipore (diluted 1:20000); eEF-2K (C-12), Santa Cruz
Biotechnology (diluted 1:500); Actin, Millipore (diluted 1:20000). The following fluorescent secondary
antibodies (Li-COR) were used at a 1:15000 dilution: Goat anti-Rabbit, 926-32211; Goat anti-Mouse, 92668070. Blots were imaged on a Li-COR Odyssey-Sa.
5.5.5 Inline size exclusion chromatography and native electrospray mass spectrometry
2+

The TR and Ca -CaM•TR complex for native ESI-MS was prepared as described above. The
samples were injected onto a MAbPac SEC-1 Size Exclusion LC column pre-equilibrated with 50 mM
ammonium acetate with a continuous flow rate of 50 µL/minute. Elution from the SEC column was
directly introduced into a Bruker maXis-II ETD ESI-QqTOF mass spectrometer. Spectral averaging of TR
2+

and Ca -CaM•TR complex were performed using the Bruker COMPASS software package. The mMass
software was then used for baseline correction and smoothing with a 5 Da Gaussian smoothing function.
The free CaM spectra were similarly processed except the use of a 0.05 Da Gaussian smoothing
function.
5.5.6 Hydrogen/deuterium exchange mass spectrometry (HXMS)
2+

Protein samples (TR in the apo state and the Ca -CaM•TR complex) for HXMS experiments
were purified as described above. To obtain the deuterium uptake on the global level, exchange was
2+

initiated by the addition of 2 µL of the sample (either free TR or the Ca -CaM•TR complex) in buffer A to
98 µL of exchange buffer (20 mM Tris, 200 mM NaCl, 2 mM DTT pH 7.5 in 99.9% D2O) to a final protein
concentration of 2 µM. Samples were then incubated at room temperature for the desired exchange time
2+

(5, 10, 30 and 240 minutes for TR and 5, 10, 30, 60 and 240 minutes for the Ca -CaM•TR complex). The
exchange was quenched by 2 minutes of incubation on ice followed by the addition 100 µL of quench
buffer (0.1 M guanidinium hydrochloride, 0.4% formic acid) to reduce the pH to 2.4. All subsequent steps
were performed in an ice bath. The quenched samples were desalted using a 10 µL C8 Opti-lynx II trap
cartridge (Optimize Technologies) at a flow rate of 0.12 mL/minute using 0.25% formic acid as the mobile
phase. The protein was then eluted using a gradient from 10% acetonitrile, 0.25 % formic Acid (Buffer A)
to 95% acetonitrile, 0.25% formic acid (Buffer B) at a flow rate of 0.1 mL/minute. To determine the
deuterium uptake at each time-point, the average mass of a non-deuterated reference sample was
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subtracted from the average mass of each deuterated sample.
To acquire local exchange profiles (D2O incubation for 5, 10, 30 and 60 minutes was used for
2+

both TR and the Ca -CaM•TR complex), the quenched protein sample was immediately injected over an
Enzymate BEH Pepsin Column (Waters) with the resulting peptides being desalted by a 10 µL C8 Optilynx II trap cartridge (Optimize Technologies). The digestion with subsequent desalting was performed at
a flow rate of 0.12 mL/minute using 0.25% formic acid as the mobile phase. The mixture of peptides was
then resolved with a 50 × 1 mm Hypersil Gold C18 column (Thermo Scientific) and eluted directly into the
maXis-II ETD ESI-QqTOF spectrometer using a flow rate of 0.04 mL/minute. The resulting peptides were
identified using the Bruker COMPASS software package. The extent of exchange was assessed using
the commercial software HDExaminer (Sierra Analytics). HDExaminer identified exchanged peptides from
raw MS data based on peptide retention times from the COMPASS analysis of an unlabeled reference
sample. HDExaminer then calculated the deuterium uptake of each peptide after specified exchange
times. The percent deuterium uptake relative to the theoretical maximum for each peptide was then
averaged across replicate experiments for each time point. The difference between the average percent
2+

deuterium uptake of apo TR and the Ca -CaM•TR heterodimer peptides was then taken to identify
regions that experience changes in protection upon CaM binding. All experiments were conducted in
triplicate, though some peptides could not be unambiguously identified in some replicates. All peptides
used in the analysis were observed in duplicate or triplicate for each time point.
5.5.7 Chemical crosslinking mass spectrometry (XLMS)
Proteins for chemical crosslinking were purified through size exclusion chromatography (as
above) using columns pre-equilibrated with a buffer containing 50 mM MES, 200 mM NaCl, 1 mM CaCl2
at pH 6.5) immediately prior to carrying out chemical crosslinking experiments. The crosslinking reaction
was carried out according to manufacturer’s instructions. Briefly, 0.4, 0.8 or 1.6 mg of 1-ethyl-3-(3dimethylaminopropyl)

carbodiimide

hydrochloride

(EDC)

and

1.1,

2.2

or

4.4

mg

of

N2+

hydroxysulfosuccinamide (sulfo-NHS), respectively, were dissolved directly into 1 mL of 50 µM Ca CaM•TR and incubated at room temperature. After 15 minutes, β-mercaptoethanol was added to a final
concentration of 0.14%. The samples were then incubated at room temperature for 30 minutes, after
which a 300 µL aliquot was removed and the reaction was quenched on ice with 50 mM glycine. Another
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300 µL aliquot was similarly collected and quenched at 1 hour of reaction time. The remaining 400 µL was
incubated for an additional hour and similarly quenched. The samples were then digested for 16 hours
with 10µg/ml of MS grade trypsin (Fisher) at 37 °C. The protease digestion was quenched with 1 mM
PMSF protease inhibitor. The resulting mixture of peptides was subjected to HPLC-ESI-MS/MS analysis
using Acclaim 300 2.1 × 150 mm C18 column (Thermo Scientific) and maXis-II ETD ESI-QqTOF mass
spectrometer.

A database of expected crosslinked peptides was generated with xComb
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and a

MASCOT server (Matrix Science) was used to search the XLMS data for the predicted peptides. False
positive peptides were identified by comparison of the crosslinked data sets to an untreated control
sample and analysis of CID fragmentation patterns.
5.5.8 Production of

13

1

C, H Ile-δ 1–labeled TR

Plasmids encoding His6-SUMO-TR and corresponding point mutants were transformed into E.
coli C41 (DE3) cells. Each Ile in TR was mutated one at a time to Leu (except I232 that was mutated to
Ala and I522 that was mutated to Ser) by site-directed mutagenesis using the Phusion Master Mix with
HF Buffer and Q5 High-Fidelity 2X Master Mix (New England BioLabs). Fresh C41 (DE3) colonies were
inoculated into starter LB cultures supplemented with ampicillin (100 mg/L), grown at 37 ºC until the A600
reached 0.6, centrifuged (4000 × g for 15 minutes at 4 ºC). The cell pellet was re-suspended in a starter
M9 medium prepared in D2O and grown overnight. The overnight culture was inoculated into a 0.5 L D2Obased M9 medium supplemented with 1 g/L

15

2

NH4Cl and 2 g/L H-glucose and grown at 37 ºC. When the

13

A600 reached 0.5, 50 mg/L (methyl- C, 3,3-d2) α-ketobutyric acid (Cambridge Isotope Laboratories) was
added to the growth that was incubated for 1 hour, followed by induction with 0.5 mM IPTG at 18 ºC for
22 hours. Cells were harvested by centrifugation (2820 × g for 30 minutes at 4 ºC) and re-suspended in
lysis buffer (50 mM Tris at pH 7.8, 500 mM NaCl, 150 mM KCl, 5 mM β-mercaptoethanol, 20 mM
imidazole, and 1 mM CaCl2). After lysis by sonication, the lysate was centrifuged (15,000 × g for 30
minutes at 4 ºC). The supernatant was extracted and incubated with Ni-NTA beads (Qiagen) for 1 hour at
4 ºC. The beads were poured into an Econo-Column (Bio-Rad), washed with 10 column volumes of lysis
buffer, and eluted with elution buffer (lysis buffer containing 250 mM imidazole). ULP1 protease (1:1000
ULP1 to fusion mass ratio) and λ-phosphatase (0.25 nanomoles) were added into the eluate, which was
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then dialyzed against 4 L dialysis buffer (20 mM Tris at pH 7.5, 150 mM NaCl, 5 mM β-mercaptoethanol,
and 1 mM MnCl2) at 4 ºC for 16 hours, using 12-14 kDa MWCO dialysis bag (Spectra/Por). Dialyzed
samples were centrifuged (15,000 × g for 30 minutes at 4 ºC), filtered (0.22 µm), and purified over a 5 mL
HiTrap Q HP (GE Healthcare Biosciences) column using a linear gradient of 0.2 – 0.8 M NaCl (20 mM
Tris at pH 7.5, 5 mM β-mercaptoethanol). The TR sample was further purified using a gel filtration column
(Superdex 200 10/300 GL, GE Heathlcare Biosciences) pre-equilibrated with NMR buffer (20 mM BisTris
at pH 6.8, 150 mM KCl, 10 mM CaCl2, 5 mM β-mercaptoethanol, and 0.1 % NaN3).
5.5.9 NMR titrations
All NMR experiments were performed at 25 ºC on a Bruker Avance spectrometer operating at
800 MHz equipped with a cryogenic probe capable of applying pulsed field gradients along the z-axis. A
37 µM sample of

13

1

15

2

C, H-Ile-δ1, U-[ N, H]-labeled TR in NMR buffer prepared in D2O was used in the

CaM-titration experiments using

13

1

C, H HMQC spectra (64 and 512 complex points in the

13

1

C and H

dimensions, respectively, with corresponding sweep-widths of 7 and 12.5 ppm). In addition to apo TR,
2

data were obtained in the presence of 0.25, 0.5, 1, 2, and 4 molar equivalents of U- H-labeled CaM. All
spectra were processed using NMRPipe
resonances were obtained using

13

130

and analyzed using NMRViewJ

1

C, H SOFAST-HQMC

180

spectra of

at 700 MHz (64 or 96 or 128 and 512 complex points in the

13

13

131

. Assignment of the Ile-δ1

1

C, H-Ile-δ1-labeled TR mutants

1

C and H dimensions, respectively, with

corresponding sweep-widths of 7 and 13.3 ppm) in the absence/presence of various molar ratios of
unlabeled CaM. The concentrations of the various Ile mutants of TR in the NMR samples varied from 11.4
to 46 µM.
5.5.10 Generation of a computational model of the KD•CTR complex
For the first step in the generation of the KD•CTR496-725 complex, the structure of a C-terminal
fragment encompassing residues L496-E725 was generated utilizing the NMR structure of the HR23
construct (G562-E725) together with ab initio modelling

186

and RosettaDock

187

as implemented in the

Rosetta3.7 suite. Fragment libraries for ab-initio modeling were generated using the Robetta server

188

.

Initially, a fragment corresponding to residues V502-S575 (CTR502-575) was modeled ab initio. The
calculation resulted in partial convergence for the fragment encompassing residues E541-S575 (CTR541-
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575)

that was consistently modeled as containing two antiparallel helices. Next, from the lowest energy

structure belonging to the HR23 NMR ensemble, we extracted the folded portion that corresponds to
CTR597-725. A loop spanning residues Q624-C631 was also removed, since it could favor a different
conformation in the presence of the neighboring regions that were missing in the NMR construct. The
previously described CTR541-575 fragment was then docked onto the CTR597-725 fragment using two
harmonic restraints and a 15 Å tolerance between the N-terminal residue (G597) of CTR597-725 and the Cterminal residue of CTR541-575 (S575), and between residues L564 of CTR541-575 and D609 of CTR597-725, in
order to preserve the expected anti-parallel orientation of the helices. The predicted loop that links these
two regions (S575-G597), as well as the Q624-C631 loop were then modeled using the kinematics
closure (KIC)

189

method implemented in Rosetta, resulting in the final model for CTR541-725. It is notable

that the newly constructed Q624-C631 loop assumed a conformation that was similar to that observed in
the experimental NMR structure of the HR23 construct.
Next, we modeled a CTR496-562 fragment; it should be noted that this in-silico construct shares the
541-562 helical region with the previously described CTR541-725 model. For CTR496-562 however, the native
eEF-2K sequence

541

EKGEEWDQESAVFHLEHAANLG

was modified using RosettaRemodel

190

562

(that forms the N-terminal helix of CTR541-725)

, such that the hydrophobic residues that contact the neighboring

helix on the C-terminal side (bold residues) (in the context of the modelled CTR541-725) were converted to
polar residues to form an artificial capping interface in the context of CTR496-562. This was done in order to
prevent packing of the native hydrophobic face into the hydrophobic interior of CTR496-562 and thus
resulting
541

in

non-native

contacts.

EKGEEWDQESQVFHKEHKSNQS

562

This

led

to

the

following

sequence:

. With these mutations in place, an ab initio model of CTR496-562

was then constructed. The resulting CTR496-562 was then superimposed onto the modelled CTR541-725
using their overlapping regions (residues E541-G562). At this point the redundant E541-G562 fragment
within the CTR496-562 construct was removed, together with the neighboring G536-C540 loop. On the
CTR541-725 model, the disordered E541-D546 fragment was also removed. A continuous CTR496-725 was
obtained by modelling the missing loops using the KIC methodology. Finally, the resulting structure of
CTR496-725 was relaxed in the Rosetta force field using default parameters.
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Next, the CTR496-725 fragment was docked onto the modeled KD (H103-P330) using RosettaDock.
The observed inter-domain crosslinks (K516/K517-D248 and K517/K520-D248/D249; IntraTR-2, 3 in
Table 5.1) were used as ambiguous restraints using a flat harmonic scoring function with zero penalty
range of 15 Å. A total of 20000 calculations were attempted, of these, 1205 resulted in no violations of
restraints and successful structure output. Docked decoys with interface energies ranging from -5 to -10
(Rosetta Energy Units) were used for further analysis (264 total). The interface RMSD values of the
decoys were calculated within RosettaDock using the local refinement protocol with one round of
minimization which leads to rescoring of all decoys with the lowest energy decoy as reference.
5.5.11 Small angle X-ray scattering (SAXS)
2+

The Ca -CaM•TR complex for SAXS experiments was purified as described above. Samples
were concentrated using Amicon Ultra 10K MWCO spin concentrators (Millipore) to final concentrations of
2+

1.9 or 6.4 mg/ml (for Ca -CaM•TR). Flow through from the concentrator was used as a reference to
subtract buffer contribution from the scattering data. All experiments were performed on a Rigaku
BioSAXS 1000 instrument equipped with a Dectris Pilatus 100K detector attached to one port of an FRE+
Superbright rotating copper anode X-ray generator.
Scattering data was analyzed using the ATSAS 2.8.3 software package
distribution function was calculated using GNOM
DAMMIF

192

181

191

. The particle

and the molecular envelopes were calculated using

. In all 20 structures were calculated for each concentration and selected based on normalized

spatial deviation values (NSD) and an average envelope was determined using DAMAVER
frequency map and the average model computed by DAMAVER was utilized in a DAMMIN

193

194

. The

run to

generate the final refined molecular envelope. In addition, SAXS data was also collected for TR alone at
concentrations of 3 mg/mL, 5 mg/mL and 10 mg/mL. No detailed analysis was performed in these cases
since an initial inspection suggested concentration dependent aggregation.
2+

The 6.4 mg/mL SAXS dataset was used together with the structures of the Ca -CaM•CBD
complex

53

(a representative structure was chosen from the NMR ensemble) and the KD•CTR496-725
2+

complex (from above) were to generate the overall topology of the Ca -CaM•TR complex using
CORAL

182

. To allow some flexibility between modules,
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2+

residues W99 and A100 were removed from the C-terminus of CBD in the Ca -CaM•CBD complex and
the new C-terminal residue (P98) was linked to A108 of the KD
(after removing the H103-I107 segment at the N-terminus) in the KD•CTR496-725 complex using a 9glycine linker. The C-terminal P330 of the KD was then linked to the N-terminal L496 of the CTR both in
the context of the KD•CTR496-725 complex using a 40-glycine linker (including the 6-glycine linker native to
TR). Calculations were performed using the entire SAXS dataset or the range listed in Table 5.3
2+

(q=0.0238-0.2293) using different orientations of Ca -CaM•CBD relative to the KD•CTR496-725 complex,
including one in which the former was placed at a significant distance without linking the Cterminus of the CBD to the N-terminus of the KD in the starting configuration. Overall similar organization
of domains was obtained in all cases irrespective of starting configuration. The final structure generated
by CORAL was superimposed on the DAMMIN refined molecular envelope (from above) using
SUPCOMB

195

.
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Chapter 6 – Future Directions
6.1 Overview of Future Directions
The mechanism of CaM-mediated eEF-2K activation was successfully characterized by
combining biochemical and biophysical methods including NMR, hydrogen/deuterium exchange mass
spectrometry, chemical crosslinking and SAXS. As described in Chapters 4 and 5, we have generated a
structural model for the previously uncharacterized C-terminal region of eEF-2K as well as a model of the
2+

Ca -CaM•TR complex. Further, we have identified regions within TR that are altered upon CaM binding.
While this is a critical first step in eEF-2K activation, phosphorylation of T348 represents the next critical
step required for eEF-2K to adopt its fully active conformation (generating state S3 from state S2 in
Figure 1.2). Given that our results suggest that CaM binding has an allosteric effect on the phosphate
binding pocket into which phospho-T348 docks prior to the phosphorylation event. This raises intriguing
possibilities of coupling between these two steps of the proposed activation pathway described earlier.
Additionally, a second site of auto-phosphorylation (also a PKA target), S500 (Figure 1.2), has been
shown to have a complementary role in eEF-2K activation.

196,197

In addition, to the events subsequent to

T348 phosphorylation, analysis the structural effects when both T348 and S500 are phosphorylated
would provide insight into the functional roles characterization of the later steps of the eEF-2K activation
pathway.
6.2 Characterization of the Mechanism of eEF-2K Activation through T348 Phosphorylation
The experimental approach described in Chapter 5 could be applied to characterize the
conformational following T348 phosphorylation with a few minor modifications. We anticipate that
interaction of phosphorylated T348 with the phosphate binding pocket within the C-lobe will further
stabilize an active conformation of the kinase domain. HXMS experiments will yield information about
structural perturbations and dynamics changes in response to T348 phosphorylation. NMR analysis of Ileδ1 chemical shifts could provide an orthogonal approach to further identify residues that are perturbed
upon T348 phosphorylation. SAXS analysis of these activation states can also be used to further
characterize major changes in the overall shape of the protein in response to T348 phosphorylation.
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6.2.1 Isolation of T348 phosphorylated TR
Isolation of TR phosphorylated on T348 would greatly facilitate analysis of the second step of the
proposed eEF-2K activation pathway (Figure 1.2). Multiple approaches could be taken to generate a
homogeneously T348 phosphorylated species without additional phosphorylation events. To ensure that
we control the phosphorylation state of TR, we first treat the protein sample with a phosphatase to
2+

generate a homogeneously dephosphorylated species. Incubation of eEF-2K with Ca -CaM and
2+

Mg •ATP in vitro has been show to result in rapid autophosphorylation of eEF-2K on T348 as well as
phosphorylation of S500 on a much longer timescale.

36

Due to significantly slower autophosphorylation

rates of S500 compared to T348, optimization of the autophosphorylation assay may allow the production
of homogeneously phosphorylated T348/non-phosphorylated S500. The phosphorylation state of TR can
be characterized by mass spectrometry of the intact protein (to determine the number of phosphorylated
residues within TR) and trypsin digested peptides (to determine the location of the phosphorylated
residues). If heterogeneous phosphorylation states are unavoidable, a S500A mutant form of TR could be
utilized to ensure that only T348 is the only available autophosphorylation site. This mutant would allow
complete and homogeneous phosphorylation of T348 through extended in vitro autophosphorylation of
TR. However, it would then be important to confirm that the S500A mutation does not lead to any
changes in the overall structure/dynamics of TR.
6.2.2 HXMS Analysis of Step Two (T348 Phosphorylation) of the eEF-2K Activation Pathway
A similar methodological approach as described in Chapter 5 could be utilized to characterize the
mechanism through which phosphorylation of T348 mediates activation of eEF-2K. Briefly, intact mass
2+

HXMS of dephosphorylated and T348 phosphorylated Ca -CaM•TR would be performed to determine
the relevant time range to investigate as well as characterize the global effect of T348 phosphorylation on
the structure of TR and CaM. Local exchange rates will then be determined to identify regions within TR
and CaM that are altered by T348 phosphorylation. Comparison of the T348 phosphorylated state of TR
2+

in the presence and absence of CaM would also allow further dissection of the effects of Ca -CaM
mediated activation as opposed to T348 phosphorylation.
We anticipate that phosphorylation of T348 will reduce the rate of deuterium uptake by TR
compared to the fully dephosphorylated CaM bound state. This is due to stabilization of a stable active
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conformation of TR, which is likely to be more compact and less dynamic than dephosphorylated TR. As
described above, CaM induces allosteric changes to the phosphate binding pocket that phosphorylated
T348 docks into (Chapter 5). While it is not expected that phosphorylated T348 directly interacts with
CaM bound to TR, it is possible that allosteric communication between the phosphate binding pocket and
the CaM binding interface may alter or stabilize CaM binding thus resulting in changes in the protection of
CaM bound to TR.
While it is impossible to predict all of the local effects of T348 phosphorylation a priori, we
anticipate that the phosphate binding pocket will become more protected in the T348 phosphorylated
state. We suspect that coordination of the T348 linked phosphate group by K205, R252, and T254

37

of

eEF-2K would decrease the dynamic behavior of this region, thus reducing the rate of local deuterium
uptake. Sequestering a peptide onto the C-lobe of the kinase domain would also reduce the average
solvent exposure of the surface area in this region, which would be expected to further reducing the rate
of deuterium uptake. Our model of the spatial orientation domains within TR suggests that the pocket is
adjacent to the N terminal region of the C-terminal domain, which could lead to the possibility that binding
of phosphorylated T348 to the phosphate binding pocket would also perturb this region of the C-terminal
domain.
6.2.3 NMR Analysis of Step Two (Thr348 Phosphorylation) of the eEF-2K Activation Pathway
Comparison of

13

1

C, H HMQC spectra of

13

1

C, H-Ile-δ1-labeled dephosphorylated and T348

2+

phosphorylated Ca -CaMTR offers an orthogonal method to further characterize this system. Three of
the Ile residues within TR (I518, I237, I251) are located in proximity to the phosphate binding pocket. We
anticipate that these residues will all be significantly perturbed by T348 phosphorylation.
6.3 Characterization of the Mechanism of eEF-2K Activation through Additional Phosphorylation
Events
Phosphorylation of S500 or a phosphomimetic mutant S500D have been shown to induce CaMdependent but calcium independent activation of eEF-2K (Figure 6.1).

149,173,196

To characterize the

mechanism of this activation pathway a similar approach could be taken as described in Section 6.2
above. A S500D mutant of the TR construct would facilitate these studies by ensuring a homogeneous
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sample that could be phosphorylated on T348 as described above. Due to the calcium independent
activation it would be especially interesting to determine the effect of this construct on the conformation of
CaM. Therefore, the analysis of free CaM would be a useful reference for comparison to the S500D-TR
(and/or S500D, pT348-TR) bound states.
While all of the additional regulatory phosphorylation sites of full-length eEF-2K (see Figure 1.1)
are missing in the TR construct (see Figure 5.1A), the structural and dynamics changes upon additional
regulatory phosphorylation will have to rely on full-length eEF-2K, that has proven to be less biophysically
tractable than the TR construct. Thus, further optimization of sample/experimental conditions will be
needed to pursue analogous studies on full-length eEF-2K.
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Figure 6.1 – Proposed three-step mechanism for eEF-2K activation. Resting eEF-2K (state S1) forms
a complex with calcium bound calmodulin (state S2*) and undergoes a conformation transition (T1) to a
state (S2) that is able to phosphorylate on T348. Rapid auto-phosphorylation on T348, leading to an
excited state S3*, enables phosphorylated T348 to interact with a phosphate binding pocket on the C lobe
of the kinase domain, leading to a second conformation transition (T2), generating a state of eEF-2K (S3)
that has the highest activity towards its substrate eEF-2. Subsequent phosphorylation of S500 (state S4*
and S4) by eEF-2K or PKA induces CaM dependent but calcium independent activation (T3) through a
yet unknown mechanism.
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